AU2017209362B2 - Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation - Google Patents

Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation Download PDF

Info

Publication number
AU2017209362B2
AU2017209362B2 AU2017209362A AU2017209362A AU2017209362B2 AU 2017209362 B2 AU2017209362 B2 AU 2017209362B2 AU 2017209362 A AU2017209362 A AU 2017209362A AU 2017209362 A AU2017209362 A AU 2017209362A AU 2017209362 B2 AU2017209362 B2 AU 2017209362B2
Authority
AU
Australia
Prior art keywords
tert
butyl
methoxyphenol
group
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017209362A
Other versions
AU2017209362A1 (en
Inventor
Xinhua He
Tao Li
Zhenggang Liu
Xuemin Zhang
Tao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Biomedical Analysis Center of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Biomedical Analysis Center of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS, Biomedical Analysis Center of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Publication of AU2017209362A1 publication Critical patent/AU2017209362A1/en
Application granted granted Critical
Publication of AU2017209362B2 publication Critical patent/AU2017209362B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/58—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/38—Malonic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/44—Adipic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/54—Acrylic acid esters; Methacrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/606—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom having only or additionally carbon-to-carbon triple bonds as unsaturation in the carboxylic acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/80—Phthalic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

Disclosed are a hydroquinone compound, a preparation method therefor, and an application in tumour resistance or immunomodulation. The structural formula of the hydroquinone compound is as shown in formula I, wherein: X is C=O or CH

Description

CAS Registry Number: 748010-49-3; STN Entry Date: 19 Sep 2004; Chemical Name: 2-Benzofurancarboxylic acid, 2-(1,1-dimethylethyl)-4-methoxyphenyl ester CAS Registry number: 926426-70-2; STN Entry Date: 14 Mar 2007; Chemical Name: 2-Pyridinecarboxylic acid, 3,4,5-trichloro-, 2-(1,1-dimethylethyl)-4 methoxyphenyl ester EP 0045990 Al CAS Registry number: 926868-22-6; STN Entry Date: 18 Mar 2007; Chemical Name: 1,2,4]Triazolo[1,5-a]pyrimidine-6-propanoic acid, 5,7-dimethyl-2 (methylthio)-, 2-(1,1-dimethylethyl)-4-methoxyphenyl ester
(12) tfI1W&PieSA IW
(10) (43)E~# 2017 * 7,P]27 (27.07.2017) WI p WO 2017/125093 A1 W 1P7C/T
(51) 04"i3 &I MEDICAL SCIENCES) [CN/CN]; Th NJ4LWTTMtEx C07C271/44 (2006.01) C07C 69/16 (2006.01) -TYF 27 , Beijing 100850 (CN)o C07C271/56 (2006.01) A61K 31/325 (2006.01) C07C69/28(2006.01) A61K31/222(2006.01) (72) TtHUA: # (ZHANG, Xuemin);+: dN J4LiT C07D 265/30 (2006.01) A61K31/23 (2006.01) t E k T Y 27 V, Beijing 100850 (CN) , fi*$ C07C 69/78 (2006.01) A61P 35/00 (2006.01) (HE, Xinhua); 1 N J L v M *t E k T Y§ 27 2 7, (21) PJWFP" : PCT/CN2017/074386 Beijing 100850 (CN)0 o N (ZHOU, Tao); ' 14LJ ( $PC N4t/4M FY27 Beijing 100850 (CN) o #!TE (22) MR*- $: 2017 4 2 A 22 H (22.02.2017) |u(LIU, Zhenggang); 1: N J 0v M *t T Y 27 (, Beijing 100850 (CN)0 ** (LI, Tao); 'NLW (25) .n~'~ $$t$Z TYF 27 , Beijing 100850 (CN)o (26) c(74)1ftWA: (30)f$$W: (JEEKAI & PARTNERS); t1L tt$ 201610037849.5 2016 1 20 H (20.01.2016) CN 9 '5V ti 5 15A ) , Beijing 100055 (CN)o
*H9iTrt (BIOMEDICAL ANALYSIS CENTER, 4P): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, ACADEMY OF MILITARY MEDICAL SCIENCES) BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR,
[CN/CN]; +'bL M t l TFi 27 ', Beijing CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, Fl, 100850(CN)o GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, INSTITUTEE OF PHARMACOLOGY IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, AND TOXICOLOGY, ACADEMY OF MILITARY LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX,
(54) Title: HYDROQUINONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION IN TUMOUR RESISTANCE OR IMMUNOMODULATION
(57) Abstract: Disclosed are a hydroquinone compound, a preparation method therefor, and an application in tumour resistance or immunomodulation. The structural formula of the hydroquinone compound is as shown in formula I, wherein: X is C=O or CH2 ; Y is NH, 0 or absent; R is selec ted from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a O X'IY R substituted or unsubstituted cycloalkyl group having at least three carbon atoms, and a substituted or unsubstituted al X R kenyl group or alkynyl group having at least two carbon atoms; a substituted or unsubstituted aryl group or heteroaryl group at least containing four carbon atoms. The compound 0 slowly releases 2-tert-butyl-4-methoxyphenol in the body, overcomes the shortcoming that the half-life of 2-tert-butyl 4-methoxyphenol directly administered in the body is short (T1/2 = 0.5-lh), and maintains a stable 2-tert-butyl-4-meth oxyphenol plasma concentration (T1/2 = 12-24h). The com pound protects the phenolic hydroxyl group of 2-tert-butyl-4 methoxyphenol, prevents oxidation in the environment, and increases the environmental stability of a drug.
(57)It: o [)q~F]
W O 2017/12IIllIIIlI||lllIlIlllI||I||||||VI|||I|||||||||||||||||I| | | |I MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SN, TD, TG)o SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW o (84)~ (84)I ~ Y~t ~( I"' ,tE h ~i(f f N ~ HA ~5* #j~J ) f~~~' -fNfI # MN VT, r5tA'I T @ M21 *,(3)),o 'TftP): ARIPO (BW, GH, GM, KE, LR, LS, MW,MZ, ----IMT, -I0I NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), _) .2(h48.2(h)), (AM, AZ, BY, KG, KZ, RU, TJ, TM), r VI (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, Fl, FR, GB, GR, (MJNO 26 Zi.3 48.2(b)(vii))o HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ,
4R MO R --fX1% S~il@R M&% RL00190E aMA, lyF: n M o PWLTidXAMRl i nli fJ lt4 4 X I F X4, I , X C=O N CH 2; Y A NH, O 0Z;T Ri P T L 0 M,1-I--- :I 1
Fjff 2-,jRT M-4-P A Th3, A V 2-,jRT M-4-P )-A A #JM A(T 1/2=0.5~ lh), I(tt'I'tfJ 2-UT -4- {L(J tK{V)T2-±TM-4-F $h fllMPt (T1/2=12~24h), ZflJWYEkiA TA JWM, IA tT {LRh~
Hydroquinone Compounds, Preparation Methods therefor, and Use in Anti-Tumor or Immunomodulation therapy
Technical Field The present invention relates to a serial of hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy.
Background Solid tumor, in addition to cancer cells, also comprises fibroblast, endothelial cells, various immune cells and a great deal of extracellular matrix, and the like. The immune cells play key roles in the processes of tumor invasion, metastasis and immune escape, wherein tumor-associated macrophages (TAMs) account forconsiderable proportion in tumor interstitialcells, most of them are migrated and differentiated from peripheral blood monouclear cells, and matured under effect of tumor cells and its microenviroment.TAMs can secrete various growth factors, cytobines, immunosuppressive medium and proteolytic enzyme so as to promote development and metastasis of the tumor. The tumor-associated macrophages (TAMs) can be polarized into two kinds of phenotypes:M1 macrophage and M2 macrophage. MImacrophages, also referred as classically activatedmacrophages, with very strong pro-inflammatory and pathogen killing effect, and can promote Th1 type cell response mediated by inflammatory factors such as IL12, IL23, and the like; M2 macrophages, also referred as non classically activated macrophages, with functions of immunomodulation, tissue remodeling and pro-angiogenesis, and the like. More and more evidences show that, the tumor-associated macrophages (TAMs) play a key role of "double-edged sword" in the generation and development of malignant tumors: M1 can kill tumor cells, while M2 macrophages play a crucial role in the initiation, promotion, and metastasis of cancer cells (Cell 2010, 141:39-51.). The polarization of TAMs is closely related with the tumor microenviroment, and often presents M2 polarized state in malignant tumor. Therefore, redress the microenviroment of the tumor, inhibiting the M2polarization of TAMs can change the microenviroment of tumor cells, promote death of tumor cells, thereby inhibiting the initiation, promotion, and metastasis of the tumor. Recent study have shown that antioxidants such as 2-tert-butyl-4 methoxyphenol (BHA), Apocynin, TEMPO and NAC, and the like can inhibit generation of active oxygen radicals ROS, thereby inhibit differentiation of monocytes toward M2 macrophages, and then inhibit generation of lung cancer in K ras model mice (Cell Research 2013, 23:898-914.) However, there are also much studies showing that the antioxidants would accelerate the growth of tumor, it is disaccord with the anti-tumor activity in vivo of 2-tert-butyl-4-methoxyphenol, therefore, inhibiting generation of ROS is one factor of inhibiting the M2 polarization of TAMs by 2-tert-butyl-4-methoxyphenol, but not whole, and there are also other mechanisms for inhibiting the M2 polarization of TAMs by BHA,thereby inhibiting generation and development of the tumor (Cancer Res. 1986, 46,165-168; Cancer Res.,1985, 45:1-8.). However, paradoxically, in the early study, there are evidences showing that 2-tert-butyl-4-methoxyphenol has carcinogenic effect (Archives of Biochemistry and Biophysics 2006 , 449 , 171-177; Regulatory Toxicology and Pharmacology 47 (2007) 68-77; Food and Chemical Toxicology 2000, 38 , 1075-1084). In the literature (Cell Research 2013, 23:898-914.), a fodder of 0.75% BHA is dosed, and the generation of lung cancer was completely inhibited in K-ras model mice. However, according to differences of body surface area and species, this dosage is 7.5g/day as converting to dosage of a person with 60kg weight. This dosage substantially exceeds intaking amount of 0.5 mg/kg body weight per day as regulated in European Union and USA, and also exceeds upper limit of 0.2g/kg of 2 tert-butyl-4-methoxyphenol added in food as regulated in China. Therefore, 2-tert butyl-4-methoxyphenol cannot become a directly useable tumor therapeutic drug. Therefore, there is a need to further evaluate tumor therapeutic effects of 2-tert butyl-4-methoxyphenol.
Summary of Invention The purpose of the present invention is to provide a serial of hydroquinone compounds, preparation methods therefor, and use thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compound provided by the present inventionis as shown by formula I, and the pharmaceutically acceptable salts, hydrates or solvates thereof are also in the range to be protected by the present invention,
2 X R formula I in formula I, X is C=O or CH 2 , R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom,a substituted or unsubstituted cycloalkyl group containing at least three carbon atoms,a substituted or unsubstituted alkenyl group or alkynyl group havingat least two carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group; in formula I, Y is NH, 0 or absent; the substituent groups in R arehalogen, amino group, nitrogroup, estergroup, carbonylgroup, amino acid derivatives, natural flavone, naturalalkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide. In formula I, the number of carbon atoms of the alkyl group is 1~40, preferably 1-30, more preferably 1-25; the number of carbon atoms of the cycloalkyl group may be 3~40, preferably 330, more preferably 3-25; the number of carbon atoms of thealkenyl group or alkynyl group may be 2~40, preferably 2~30, more preferably 2~25. In formula I, the aryl group or heteroaryl group particularly may be naphthalene rings, indole, benzene rings, pyridine, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle, and the like. In formula I, X and Y are selected from any one of the folowing 1)~-3): 1)when X is C=O, Y is NH; 2)when X is CH 2 ,Y is 0; 3)when X is C=O or CH 2 , Y is absent. In one aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof,
O1 - R
0" formula I wherein: when X is C=O and Y is NH, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having 1-40 carbon atom(s), a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, benzene rings, pyridine, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; when X is C=O and Y is absent, R is selected from any one of the following groups: 1) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 2) a unsubstituted alkyl group having 7-40 carbon atoms; 3) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 4) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 5) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan or pyrrole ; 6) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 7) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or 8) a substituted aryl group or heteroaryl group containing at least four carbon atoms;the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide. The compound as shown by formula I includes but not limited to any one of the following compounds 1) ~ 66): 1) (2-tert-butyl-4-methoxyphenol) (N-benzyl)carbamate, 2)(2-tert-butyl-4 methoxyphenol) (N-n-butyl)carbamate, 3)(2-tert-butyl-4-methoxyphenol) (N isopropyl)carbamate, 4)(2-tert-butyl-4-methoxyphenol) (N-cyclohexyl)carbamate, 5)(2-tert-butyl-4-methoxyphenol)(N-phenethyl)carbamate,6)pivaloyl(2-tert-butyl-4
3a methoxyphenol-oxyl) methyl ester; 7)2-tert-butyl-4-methoxyphenol benzoate, 8)2 tert-butyl-4-methoxyphenol acetate, 9)2-tert-butyl-4-methoxyphenol nicotinate, 10)2-tert-butyl-4-methoxyphenol isonicotinate, 11)2-tert-butyl-4-methoxyphenol cyclohexenecarboxylate, 12)2-tert-butyl-4-methoxyphenol propionate, 13)2-tert butyl-4-methoxyphenol acrylate, 14)(2-tert-butyl-4-methoxyphenol) 3,4 dimethoxyphenylacetate, 15)2-tert-butyl-4-methoxyphenol butynoate, 16)bis(2-tert butyl-4-methoxyphenol) 2,2'-biphenyldicarboxylate, 17)(2-tert-butyl-4 methoxyphenol) 2-chloro-5-trifluoromethylbenzoate, 18)(2-tert-butyl-4 methoxyphenol)3-fluorophenylacetate,19)(2-tert-butyl-4-methoxyphenol)(1H
3b indole-3-yl)acetate, 20)(2-tert-butyl-4-methoxyphenol) 3-(4-fluorophenyl) propionate, 21)(2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonylpiperidine-3 formate, 22)di(2-tert-butyl-4-methoxyphenol) terephthalate, 23)(2-tert-butyl-4 methoxyphenol) 3-(3-nitrophenyl)propionate, 24)(2-tert-butyl-4-methoxyphenol) 4 phenylbenzoate, 25)(2-tert-butyl-4-methoxyphenol) 4-methylpyridine-3-formate, 26)(2-tert-butyl-4-methoxyphenol) 4-methoxypyridine-3-formate, 27)2-tert-butyl-4 methoxyphenol hexadecylate, 28)N-tert-butoxycarbonylglycine(2-tert-butyl-4 methoxyphenol)ester,29)(2-tert-butyl-4-methoxyphenol)3-fluoro-4-chlorobenzoate, 30)N-tert-butoxycarbonyltetrahydropyrrole, (2-tert-butyl-4-methoxyphenol) benzoheterocycle-3-formate, 31)(2-tert-butyl-4-methoxyphenol) 3-cyanobenzoate, 32)(2-tert-butyl-4-methoxyphenol)N-tert-butoxycarbonylalaninate, 33)(2-tert-butyl 4-methoxyphenol) 2-naphthoate, 34)di(2-tert-butyl-4-methoxyphenol) malonate, 35)(2-tert-butyl-4-methoxyphenol) 3,6-dichloropyridazine-4-formate, 36)(2-tert butyl-4-methoxyphenol) 1-methylcyclopropyl formate, 37)(2-tert-butyl-4 methoxyphenol) 2-indoleformate, 38)(2-tert-butyl-4-methoxyphenol) 2-chloro-3 picolinate,39)(2-tert-butyl-4-methoxyphenol)2-thiopheneacetate,40)(2-tert-butyl-4 methoxyphenol) 3-(4-methylphenyl)-propionate, 41)(2-tert-butyl-4-methoxyphenol) propiolate,42)(2-tert-butyl-4-methoxyphenol)2-phenylpropionate,43)(2-tert-butyl 4-methoxyphenol) 2-fluoropropionate, 44)(2-tert-butyl-4-methoxyphenol) cyclohexyl acetate, 45)(2-tert-butyl-4-methoxyphenol) cyclopentanecarboxylate, 46)(2-tert-butyl-4-methoxyphenol) adamantaneacetate, 47)(2-tert-butyl-4 methoxyphenol) cyclopropylacetate, 48)(2-tert-butyl-4-methoxyphenol) N-tert butoxycarbonylpiperidine-4-formate, 49)(2-tert-butyl-4-methoxyphenol) octanoate, 50)(2-tert-butyl-4-methoxyphenol) 7-oxooctanoate, 51)(2-tert-butyl-4 methoxyphenol) cyclohexene-2-carboxylate, 52)(2-tert-butyl-4-methoxyphenol) 2,4,5-trifluorophenylacetate, 53)(2-tert-butyl-4-methoxyphenol) 2-bromo-5-iodo benzoate, 54)(2-tert-butyl-4-methoxyphenol)2-fluoro-4-nitryl benzoate, 55)(2-tert butyl-4-methoxyphenol) N-tert-butoxycarbonylpiperidine-3-formate, 56)di(2-tert butyl-4-methoxyphenol)p-phenylenediacetate,57)(2-tert-butyl-4-methoxyphenol)4 benzoyl butyrate, 58)(2-tert-butyl-4-methoxyphenol) 3,5-dimethoxy phenylpropenoate, 59)(2-tert-butyl-4-methoxyphenol) 4-chloropyridine-2-formate, 60)(2-tert-butyl-4-methoxyphenol) N-methylpiperidine-3-formate, 61)(2-tert-butyl 4-methoxyphenol) N-tert-butoxycarbonyl-6-amino pentanoate, 62)(2-tert-butyl-4 methoxyphenol) 3,3,3-trifluoropropionate, 63)(2-tert-butyl-4-methoxyphenol) morpholin-4-yl acetate, 64)(2-tert-butyl-4-methoxyphenol) 3-(3,5-di-tert-butyl-4 hydroxy-phenyl)propionate,65)di(2-tert-butyl-4-methoxyphenol)adipate;and66)2 (2-tert-butyl-4-methoxyphenoxy)ethylacetate.
II:\Kzh\nterwovn\NRPortbl\DCC\KZ H6512006_l.docx-20/03/2018
-5
The present invention further provides a method of preparing the compound as shown by formula I, comprising the following steps (1), (2), (3) or (4): (1)when X is C=O, Y is NH, comprising the following steps: RNH2 reacts with triphosgene to obtain R-N=C=O; the compound as shown by formula I is obtained via condensation reaction of R-N=C=O with 2-tert-butyl-4-methoxyphenol;
formula I
in formula I, RNH 2 and R-N=C=O, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms and a substituted or unsubstituted aryl group or heteroaryl group; The substituent groups in R are halogen, amino group, nitro group, ester group, carbonyl group, amino acid derivatives, natural flavone, natural alkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide; in formula I, X is C=O, Y is NH; (2) when X is CH 2 ,Y is 0, comprising the following steps: obtaining the compound as shown by formula I via condensation reaction of 2-tert butyl-4-methoxyphenol sodium with the compound as shown by formula 1;
formula I formula 1 in formula I and formula 1, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group; The substituent groups in R are halogen, amino group, nitro group, ester group, carbonyl group, amino acid derivatives, natural flavone, natural alkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide; in formula I, X is CH 2 , Y is 0; (3)when X is C=O, Y is absent,that is the compound as shown by formula II, comprising the following step 1) or 2): 1)obtaining a compound as shown by formula II via condensation of 2-tert butyl-4-methoxyphenol sodium with acyl chloride as shown by formula 2;
O R 0 CI R
formula H formula 2 in formula H and formula 2, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group; The substituent groups in R are halogen, amino group, nitrogroup, estergroup, carbonylgroup, amino acid derivatives, natural flavone, natural alkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide; in formula II, X is C=O; 2)obtaining a compound as shown by formula II via condensation of 2-tert butyl-4-methoxyphenol sodium with carboxylic acid as shown by formula 3;
" 1x, 0 O RHO R formula 1 formula 3 in formula H and formula 3, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstitute dcycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group; The substituent groups in R are halogen, amino group, nitro group, ester group, carbonyl group, amino acid derivatives, natural flavone, natural alkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide; in formula II, X is C=O; (4)when X is CH 2 , Y is absent, that is the compound as shown by formula II, comprising the following step: obtaining a compound as shown by formula II via condensation reaction of 2 tert-butyl-4-methoxyphenol sodium with a compound as shown by formula 4;
O O RCI R 0 formulall formula 4 in formula II and formula 4, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group; The substituent groups in R are halogen, amino group, nitro group, ester group, carbonyl group, amino acid derivatives, natural flavone, natural alkaloid, polyethyleneglycol, polyglutamic acid or polysaccharide; X is CH 2 .
In one aspect, the present invention provides a compounds compound selected from the group consisting of 1) (2-tert-butyl-4-methoxyphenol) (N-benzyl)carbamate,
5) (2-tert-butyl-4-methoxyphenol) (N-phenethyl)carbamate, 12) 2-tert-butyl-4-methoxyphenol propionate,
18) (2-tert-butyl-4-methoxyphenol) 3-fluorophenylacetate,
20) (2-tert-butyl-4-methoxyphenol) 3-(4-fluorophenyl)-propionate, 23) (2-tert-butyl-4-methoxyphenol) 3-(3-nitrophenyl)propionate,
25) (2-tert-butyl-4-methoxyphenol) 4-methylpyridine-3-formate,
26) (2-tert-butyl-4-methoxyphenol) 4-methoxypyridine-3-formate, 31) (2-tert-butyl-4-methoxyphenol) 3-cyanobenzoate,
42) (2-tert-butyl-4-methoxyphenol) 2-phenyl propionate,
44) (2-tert-butyl-4-methoxyphenol) cyclohexyl acetate, 47) (2-tert-butyl-4-methoxyphenol) cyclopropylacetate,
52) (2-tert-butyl-4-methoxyphenol) 2,4,5-trifluorophenylacetate,
64) (2-tert-butyl-4-methoxyphenol) 3-(3,5-di-tert-butyl-4-hydroxy-phenyl) propionate,
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
In one aspect, the present invention provides a method of preparing the compound of formula I, or pharmaceutically acceptable salt, hydrateor solvatethereof, according to claim 1 or 2, comprising the following steps (1), (2), (3) or (4): (1) when X is C=O and Y is NH, the method comprises: reacting RNH2 with triphosgene to obtain R-N=C=O; obtaining the compound of formula I via a condensation reaction of R-N=C=O with 2-tert-butyl-4-methoxyphenol;
O XY R
formula I wherein, in formula I, in RNH2 and R-N=C=0, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having 1-40 carbon atom(s), a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, benzene rings, pyridine, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethyleneglycol, polyglutamic acid or polysaccharide; and wherein in formula I, X is C=O and Y is NH; (2) when X is C=O and Y is absent, that is a compound of formula II, the method comprises the following step 1) or 2): 1) obtaining a compound as shown by formula II via condensation of 2-tert butyl-4-methoxyphenol sodium with acyl chloride as shown by formula 2;
O R 0
CI R O formula II formula 2 wherein in formula II and formula 2, R is selected from any one of the following groups: a) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide;
7a b) a unsubstituted alkyl group having 7-40 carbon atoms; c) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; d) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; e) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan, or pyrrole; f) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; g) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or h) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; and wherein in formula II, X is C=O; or 2) obtaining the compound of formula II via condensation of 2-tert-butyl-4 methoxyphenol sodium with carboxylic acid as shown by formula 3;
O R O
O HO R formula II formula 3 wherein in formula II and formula 3, R is selected from any one of the following groups: a) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; b) a unsubstituted alkyl group having 7-40 carbon atoms;
7b c) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; d) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; e) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan, or pyrrole; f) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; g) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or h) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; and wherein in formula II, X is C=O. In the above preparation method, the condensation reaction can be conducted under the conventional reaction conditions, such as room temperature, heating, reflux or ice-bath, and the like. In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I according to the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable carrier. The compound as shown by formula I, the pharmaceutically acceptable salts thereof, the hydrates or the solvates thereof may be applied to anti-tumor or immunomodulation, that is, the compound as shown by formula I may be utilized to release 2-tert-butyl-4-methoxyphenol in vivo. In another aspect, the present invention provides use of a compound according to the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the invention, in the manufacture of a
7c medicament for the treatment of a tumor or a disease/disorder associated with modulation of macrophages. In another aspect, the present invention provides a method of treating a tumor or a disease/disorder associated with modulation of macrophages comprising administering a therapeutically effective amount of a compound according to the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the invention, to a subject in need thereof. In another aspect, the present invention provides use of a compound according to the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the invention, as a prodrug for releasing 2-tert-butyl-4-methoxyphenol. The present invention verified that 2-tert-butyl-4-methoxyphenol (BHA) can inhibit the polarization effect of macrophages M2, and verified the anti-tumor metastasis effect of 2-tert-butyl-4-methoxyphenol in the mice model with Her2 breast cancer; dosing in portions the 2-tert-butyl-4-methoxyphenol dosage (50-1000 mg/kg BW) to the HER2 mice model shows obvious anti-tumor effects.
Description of Figures Figure 1 is a diagram illustrating that 2-tert-butyl-4-methoxyphenol inhibits the polarization effect of macrophages M2. Figure 2 shows the experimental results for metabolism of BHA in the mice in vivo. Figure 3 is a curve illustrating that the compound of the present invention releases BHA in the human plasma. Figure 4 is a curve illustrating that the compound of the present invention releases BHA in mice in vivo.
7d
Detailed Description The present invention will be explained through particular examples as follows, however, the present invention is not limited thereto. All the experimental methods in the following examples are conventional methods, unless otherwise stated; all the regents and materials can be available commericially. The present invention firstly verified that 2-tert-butyl-4-methoxyphenol (BHA) inhibits the polarization effect of macrophages M2, and verified the anti-tumor metastasis effect of 2-tert-butyl-4-methoxy phenol in the mice model with Her2 breast cancer, as shown by figure 1. In the Her2 tumor model with the breast cancer, the metastasis in head is not observed in the BHA treated group (see the left figure). The metastasis in head is obvious in mice of the blank control group, leading to eyes blind (see the right figure). At the same time, through drug metabolism tests, it is found that half-life of BHA in vivo is very short, merely 30-60 minutes, as shown by figure 2. Moreover, the present invention conducted a toxicology experiment and found that, merely central effect of partially "hangover" state is seen in the mice dosed with 600 mg/kg, that can recover after half an hour. Half of the mice with 1100 mg/kg are caused to die, and after 30-60 minutes, the symptoms of the toxic reaction in the survival mice are disappear. The toxic effect is not seen in the mice with low dose that is long term dosed for two years. Therefore, in combination with the research results of the metabolic product of 2-tert-butyl-4-methoxyphenol in the literature (having the effect of DNA damage, Food and Chemical Toxicology 1999, 37: 1027-1038), the present invention inferred that the 2-tert-butyl-4-methoxyphenol itself has the effect of anti-tumor, and the action between its metabolic product tert butylhydroquinone (TBHQ) and DNAmay result in its side effects. It is found by deep analysis that both oral absorption and metabolism of 2-tert butyl-4-methoxyphenol are very quick (the time to peak is 5 min, the mice T 1 /2=20
min), the plasma concentration for each dosing is a "pulse" with a very small time span, and at the drug concentration peak that is much higher than the minimum effective drug concentration, it is not only disadvantage to the exertion of the therapeutic effect , but also renders unnecessary toxic side effect. Therefore, if the release of 2-tert-butyl-4-methoxyphenol can be controlled, making it maintain stable plasma concentration, not only can realize the effect of increased effect and decreased toxicity, but also can effectively reduce the dose of 2 tert-butyl-4-methoxyphenol. At the same time, as 2-tert-butyl-4-methoxyphenol is a antioxidant and easily to be oxidized, therefore, the enviromental stability and the metabolism in the liver (the first pass effect is serious) are also a immediate obstacle for it to becme a drug. In order to control the release of 2-tert-butyl-4 methoxyphenol, increase the enviromental stability and reduce the first pass effect as much as possible, increase safty of the drugs, the present invention provides a prodrug 2-tert-butyl-4-methoxyphenol, and verified its release characteristics in vivo and in vitro, the cytotoxicity and the safty in vivo.
Example 1. preparation of 2-tert-butyl-4-methoxyphenol benzoate(XH2005) 2-tert-butyl-4-methoxyphenol (0.9 g, 5 mmol) dissolved in anhydrous tetrahydrofuran (20 mL) is dropwise added to a mixed liquid (10 mL) of sodium hydride (220 mg, 5.5 mmol)/ anhydrous tetrahydrofuran at 0-5°C, thereafter, reacting for one hour under the temperature. Benzoyl chloride (0.58 mL, 5 mmol)/dichloromethane (10 mL) is dropwise added to the reaction liquid obtained in the above step, reacting for two hours under the temperature, then reacting for three hours under the room temperature. The solvent is removed under reduced pressure, ethyl acetate (30 mL) and ice water (10 mL) are added to the residue, stirring to clear, separating the liquid and taking the organic layer, washing with water in 10 mLx3, drying with anhydrous sodium sulfate overnight, column chromatograohy (the eluent isethyl acetate: petroleum ether of 4: 1) to obtain 1.14 g white solid. Yield is 80%. 'H NMR (400 MHz, DMSO-d6) 6: 1.30 (s, 9H), 3.78 (s, 3H), 6.86-6.92 (m, 2H), 7.09-7.11 (d, J= 8.4Hz, 1H), 7.62-7.66 (m, 2H), 7.75-7.79 (m, 1H), 8.15-8.17 (d, J = 7.2 Hz, 2H); "C NMR (100 MHz, DMSO-d6) 6: 29.8, 34.2, 55.3, 111.1, 113.1, 125.2, 129.2, 129.3, 129.7, 134.1, 141.9, 142.3, 156.6, 165.0.
Example 2.preparation of 2-tert-butyl-4-methoxyphenol acetate (XH2006) According to the preparation method of Example 1, 2-tert-butyl-4 methoxyphenol reacts with sodium hydride, followed with acetyl chloride to obtain the compound of example 2. Then purify via recrystallization with ethylalcohol. Yield is 90%. 1H NMR (400 MHz, CDC 3) 6: 1.33 (s, 9H), 2.32 (s, 3H), 3.79 (s, 3H), 6.72-6.75 (m, 1H), 6.91-6.93 (m, 2H). 3C NMR (100 MHz, CDCl 3) 6: 21.6, 30.1, 34.6, 55.6, 110.6, 113.9, 124.6, 142.4, 142.7, 156.9, 170.2.
Example 3. 2-tert-butyl-4-methoxyphenol nicotinate (XH2010) Dissolve niacin (0.62 g, 5 mmol) in dimethylformamide (20 mL), then add dicyclohexylcarbodimide (1200 mg, 6 mmol ) and stir for 5 minutes. Add 2-tert butyl-4-methoxyphenol (900 mg, 5 mmol) and keep the temperature for 35-40°C, overnight. Remove dimethylformamide under reduced pressure. Then dissolve the residue with ethyl acetate (50 mL) and water (2 mL), stir for 20 minutes. The liquid through suction filtration was purified with column chromatography ( the eluent is ethyl acetate : petroleum ether=3: 1) to obtain the product. The yield is 73%. 1H
NMR (400 MHz, CDCl3 ) 6: 1.34 (s, 9H), 3.81 (s, 3H), 6.76-6.81 (in, 1H), 6.97-7.03 (in, 2H), 7.46-7.49 (in, 1H), 8.44-8.47 (dt, J1 = 8.4Hz, J2 = 2.0 Hz, 1H), 8.84-8.86 (dd, J1 = 4.8 Hz, J2 = 1.6 Hz, 1H), 9.41-9.42 (d, J= 2.0 Hz, 1H); 3 C NMR (100 MHz, CDCl3) 6: 30.2, 34.7, 55.6, 110.8, 114.1, 123.7, 124.7, 125.9, 137.7, 142.5, 142.7, 151.5, 154.1, 157.3, 164.6.
Example 4. 2-tert-butyl-4-methoxyphenol isonicotinate (XH2011) The preparation method is the same as that of Example3, via the condensation reaction of isonicotinic acid and 2-tert-butyl-4-methoxyphenol. Yield is 75%. 'H NMR (400 MHz, CDCl3 ) 6: 1.33 (3,9H), 3.81 (s, 3H), 6.76-6.80 (in, 1H), 6.97-7.01 (in, 2H), 8.00-8.02 (d, J= 6.2 Hz, 2H), 8.86-8.87 (d, J= 6.2 Hz, 2H). 13C NMR (100 MHz, CDCl 3 ) 6: 30.4, 34.9, 55.6, 110.8, 114.3, 123.5, 124.5, 137.0, 142.4, 151.0, 157.4, 164.9.
Example 5. preparation of 2-tert-butyl-4-methoxyphenol cyclohexenecarboxylate(XH2015) The preparation method is the same as that of Example 3. The cyclohexenecarboxylic acid and 2-tert-butyl-4-methoxyphenolester are condensed, and the yield is 75%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 1.32 (s, 9H), 1.83-1.87 (in, 1H), 2.16-2.23 (in, 3H), 2.43-2.45 (in, 2H), 2.81-2.84 (in, 1H), 3.79 (s, 3H), 5.75 (d, J= 1.1 Hz, 2H), 6.71-6.74 (in, 1H), 6.85-6.87 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J = 3.0 Hz, 1H). 1C NMR (100 MHz, CDCl 3 ) (ppm): 24.5, 24.9, 27.4, 30.0, 34.5, 6
39.9, 55.4, 110.5, 113.7, 124.4, 125.0, 126.8, 142.2, 142.9, 156.7, 174.8.
Example 6. 2-tert-butyl-4-methoxyphenol propionate (XH2016) The preparation method is the same as that of Example 3, via the condensation reaction of propionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 85%. 'H NMR (400 MHz, CDCl 3 ) 6: 1.27-1.32 (in, 12 H), 2.59-2.63 (q, J= 3.56 Hz, 2H), 3.79 (s, 3H), 6.77-6.75 (in, 1H), 6.89-6.93 (in, 2H). 13C NMR (100 MHz, CDCl 3 ) 6
(ppm): 9.0, 28.3, 30.1, 34.6, 55.5, 110.5, 113.8, 124.5, 142.3, 142.8, 156.8, 173.4.
Example 7. 2-tert-butyl-4-methoxyphenol acrylate (XH2017) The preparation method is the same as that of Example 3, via the condensation reaction of acrylic acid and 2-tert-butyl-4-methoxyphenol, the yield is 55%. 1H
NMR (400 MHz, CDC1 3 ) 6 (ppm): 6.94-6.97 (m, 2H), 6.77-6.75 (m, 1H), 6.60 (m, 1H), 6.36 (m, 1H), 6.03-6.06 (d, J= 24 Hz, 1H), 3.81 (s, 3H), 1.33 (s, 9H) 3C NMR (100 MHz, CDCl 3 ) ( (ppm): 156.8, 142.5, 132.6, 128.5, 124.5, 113.9, 110.5, 55.5, 34.6,30.0.
Example 8. (2-tert-butyl-4-methoxyphenol) 3,4-dimethoxyphenylacetate (XH2018) The preparation method is the same as that of Example 3, via the condensation reaction of 3,4-dimethoxyphenylacetic acid and 2-tert-butyl-4-methoxyphenol, and the yield is 83%. 'H NMR (400 MHz, CDCl 3) (gpm): 6.92-6.84 (m, 5H), 6.72-6.68 (m, 1H), 3.88 (s, 6H), 3.82(s, 2H), 3.78 (s, 3H), 1.27 (s, 9H). 3C NMR (100 MHz, CDCl3 ) 5 (ppm): 170.8, 157.0, 149.1, 148.4, 142.9, 142.5, 125.7, 124.5, 122.0, 113.9, 112.7, 111.3, 110.6, 56.1, 56.0, 55.6, 41.8, 34.6, 30.0.
Example 9. 2-tert-butyl-4-methoxyphenol butynoate (XH2019) The preparation method is the same as that of Example 3, via the condensation reaction of butynoic acid and 2-tert-butyl-4-methoxyphenol, and the yield is 41%. 1H NMR (400 MHz, CDC 3 ) 6: 1.35 (s, 9H), 2.07 (s, 3H), 3.82 (s, 3H), 6.77-6.75 (m, 1H), 6.94-6.97 (m, 2H). 3C NMR (100 MHz, CDC 3 ) 6 (ppm): 29.5, 30.2, 34.7, 55.6, 72.6, 88.1, 110.6, 114.0, 124.5, 142.1, 142.7, 153.0, 157.3.
Example 10. bis(2-tert-butyl-4-methoxyphenol)2,2'-biphenyldicarboxylate (XH2020) The preparation method is the same as that of Example 3. 2,2' biphenyldicarboxylic acid and 2-tert-butyl-4-methoxyphenol are reacted based on the feeding ratio in the molar ratio of 1: 2, and the yield is 62%. 'H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.26 (s, 9H), 3.76 (s, 6H), 6.65-6.68 (m, 2H), 6.77-6.79 (m, 2H), 6.87-6.88 (m, 2H), 7.26-7.29 (m, 2H), 7.45-7.48 (m, 2H), 7.55-7.58 (m, 2H), 8.19 8.21 (dd, J1 = 7.8 Hz, J2 = 1.4 Hz, 2H). 3C NMR (100 MHz, CDC 3)3ppm):28.8, 33.2, 54.2, 109.2, 112.4, 123.2, 126.2, 127.6, 129.1, 130.7, 141.3, 141.5, 142.8, 155.4,164.4.
Example 11. (2-tert-butyl-4-methoxyphenol) 2-chloro-5 trifluoromethylbenzoate(XH2021) The preparation method is the same as that of Example 3, via the condensation reaction of 2-chloro-5-trifluoromethylbenzoic acid and 2-tert-butyl-4-methoxyphenol, and yield is 74%. 1H NMR (400 MHz, CDC 3) 6 (ppm): 1.38 (s, 9H), 3.83 (s, 3H),
6.80-6.82 (m, 1H), 6.99 (m, 1H), 7.06-7.08 (m, 1H), 7.60-7.64 (m, 1H), 7.74-7.78 (m, 1H), 8.32 (s, 1H), 13C NMR (100 MHz, CDCl 3 ) 6 (ppm): 30.2, 34.7, 55.6, 110.8, 114.1, 124.5, 128.8, 129.7, 130.5, 132.3, 138.5, 142.6, 157.4, 163.5.
Example 12. (2-tert-butyl-4-methoxyphenol) 3-fluorophenylacetate (XH2022) The preparation method is the same as that of Example 3, via the condensation reaction of 3-fluorophenylacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 80%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.23 (s, 9H), 3.78 (s, 3H), 3.88 (s, 2H), 6.68-6.71 (m, 1H), 6.81-6.85 (m, 2H), 6.90-7.10 (m, 1H), 7.12-7.18 (m, 1H),7.32 7.38 (m, 1H), 3 C NMR (100 MHz, CDCl 3 ) 6 (ppm): 29.9, 34.5, 41.7, 55.5, 110.5, 113.8, 114.3, 114.5, 116.6, 124.3, 125.3, 130.1, 130.2, 135.3, 135.4, 142.3, 142.6, 156.9, 161.9, 164.1, 169.8.
Example 13. (2-tert-butyl-4-methoxyphenol) (1H-indole-3-yl)acetate (XH2023) The preparation method is the same as that of Example 3, via the condensation reaction of 1H-indole-3-acetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 65%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.32 (s, 9H), 3.81 (s, 3H), 6.66-6.70 (m, 2H), 6.78-6.82 (m, 1H), 6.85-6.90 (m, 1H), 7.12-7.42 (m, 2H), 7.67 (m, 1H),8.32 (s, 3 1H), C NMR (100 MHz, CDC 3 ) (ppm): 30.0, 32.1, 34.7, 55.7, 107.9, 110.6, 111.0, 111.5, 113.9, 114.2, 119.0, 119.9, 122.4, 123.6, 124.6, 124.7, 132.5, 143.2, 143.7, 157.0, 157.5, 163.7, 171.2.
Example 14. (2-tert-butyl-4-methoxyphenol) 3-(4-fluorophenyl)-propionate (XH2024) The preparation method is the same as that of Example 3, via the condensation reaction of 3-(4-fluorophenyl)-propionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 64%. 1H NMR (400 MHz, CDC 3) 6 (ppm): 1.28 (s, 9H), 2.88 (m, 2H), 3.06 (m, 2H), 3.82 (s, 3H), 6.52 (m, 1H), 6.79 (m, 1H), 6.91 (m, 1H), 6.99 (m, 2H),7.25 (m, 2H). 13C NMR (100 MHz, CDCl 3 ) ( (ppm): 30.0, 34.4, 36.6, 55.4, 110.5, 111.7, 113.7, 115.2, 115.4, 124.4, 129.9, 135.7, 142.2, 142.5, 156.8, 160.3, 162.8,171.6.
Example 15. (2-tert-butyl-4-methoxyphenol) N-tert butoxycarbonylpiperidine-3-formate(XH2025) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonylpiperidine-3-formic acid and 2-tert-butyl-4 methoxyphenol, the yield is 60%. 1H NMR (400 MHz, CDCl 3 ) 6 (pm). 1.32 (s, 9H), 1.47 (s, 9H), 1.76-1.82 (m, 2H), 2.22-2.26 (m, 1H), 2.79 (m, 1H), 2.84-2.88 (m, 1H), 3.16-3.20 (m, 1H), 3.82 (s, 3H), 3.97-4.02 (m, 1H), 4.33-4.36 (m, 1H), 6.68 (m, 1H), 6.83 (m, 1H),6.92 (m, 1H), 3C NMR (100 MHz, CDCl 3) 6 (ppm): 24.4, 27.5, 28.6, 29.7, 30.2, 34.8, 42.1, 55.7, 110.8, 113.9, 124.6, 142.8, 154.8, 157.1,172.6.
Example 16. di(2-tert-butyl-4-methoxyphenol) terephthalate (XH2026) The preparation method is the same as that of Example 3. p-phthalic acid (5 mmol) and 2-tert-butyl-4-methoxyphenol(10 mmol) are condensed, the yield is 55%. 'H NMR (400 MHz, CDC 3 ) 6 (gpm):1.37 (s, 18H), 3.83 (s, 6H), 6.80-6.83 (m, 2H), 7.00-7.05 (m, 4H),8.38 (s, 4H),3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 30.1, 34.6,55.5, 110.7, 113.9, 124.5, 130.4, 134.1, 142.5, 142.6, 157.1,164.5.
Example 17. (2-tert-butyl-4-methoxyphenol) 3-(3-nitrophenyl)propionate (XH2028) The preparation method is the same as that of Example 3, via the condensation reaction of 3-(3-nitrophenyl)propionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 70%. 1H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.33 (s, 9H), 2.94-2.99 (t, J= 7.2 Hz, 2H ), 3.14-3.20 (t, J= 7.2Hz, 2H), 3.78 (s, 3H), 6.69-6.73 (m, 1H), 6.80-6.83 (d, J= 8.8 Hz, 1H), 6.89-6.90 (d, J= 2.1 Hz, 1H), 7.45-7.50 (m, 1H), 7.61-7.64 (m, 1H), 8.08-8.11 (m, 1H), 8.14-8.16 (m, 1H). 3C NMR (100 MHz, CDC 3) 6 (ppm): 30.2, 34.5, 36.0, 55.7, 110.7, 114.1, 121.9, 123.5, 124.6, 129.7, 135.2, 142.3, 142.6, 148.5, 157.1, 171.4.
Example 18. (2-tert-butyl-4-methoxyphenol) 4-phenylbenzoate (XH2029) The preparation method is the same as that of Example 3, via the condensation reaction of 4-phenylbenzoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 80%. 1H NMR (400 MHz, CDCl3) (ppm).' 1.38 (s, 9H), 3.80 (s, 3H), 6.78-6.80 (m, 1H), 6.98-7.04 (m, 2H), 7.18-7.22 (m, 2H), 7.63-7.65 (m, 2H), 7.72-7.74 (m, 2H), 8.28 8.30 (m, 2H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 30.1, 34.6,55.5, 110.6, 113.8, 124.7, 127.3, 128.3, 128.5, 130.7, 139.8, 142.6, 142.8, 146.3, 156.9, 165.6.
Example 19. (2-tert-butyl-4-methoxyphenol) 4-methylpyridine-3-formate (XH2030) The preparation method is the same as that of Example 3, via the condensation reaction of 4-methylpyridine-3-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 80%. 1H NMR (400 MHz, CDC 3) 6 (ppm): 1.38 (s, 9H), 2.68 (s, 3H), 3.82
(s, 3H), 6.78-6.81 (m, 1H), 6.98-6.99 (m, 1H), 7.02-7.04 (m, 1H), 7.33-7.35 (m, 1H), 8.34-8.36 (m, 1H),9.31-9.32 (d, J= 1.68 Hz, 1H), "C NMR(100 MHz, CDCl 3) 6: 24.9, 30.2, 55.5, 110.7, 114.0, 123.4, 124.7, 138.0, 150.4, 156.4, 157.1, 164.0, 164.7.
Example 20. (2-tert-butyl-4-methoxyphenol) 4-methoxypyridine-3-formate (XH2031) The preparation method is the same as that of Example 3, via the condensation reaction of 4-methoxypyridine-3-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 75%. Due to ortho-methoxy group, a pair of peaks of the stereoisomers resulted from the chiral plane can be seen in NMR, the proportion of the two stereoisomers is 1:2. 1H NMR (400 MHz, CDC 3 ) 6: 1.33 (s, 9H), 3.81 (s, 3H), 3.82 & 4.00 (s, 3H), 6.76-6.81 (m, 1H), 6.97-7.01 (m, 2H), 7.47-7.48 & 8.04-8.05 (m, 1H), 7.55-7.58 & 7.93-7.95 (m, 1H), 8.35-8.37& 8.63-8.64 (m,1H ). 3C NMR (100 MHz, CDC 3 ) 6: 30.0, 34.5, 53.8, 55.3, 110.5, 111.6, 113.8, 115.9, 124.3, 139.9, 142.3, 147.9, 150.8, 152.6, 157.1, 157.3, 163.1, 164.1, 164.8.
Example 21. 2-tert-butyl-4-methoxyphenol hexadecylate (XH2033) The preparation method is the same as that of Example 3, via the condensation reaction of hexadecylic acid and 2-tert-butyl-4-methoxyphenol, the yield is 75%. 1H
NMR (400 MHz, CDCl3 ) 5 (ppm): 0.88 (m, 3H), 1.25-1.33 (m, 34H), 1.71-1.79 (m, 2H), 2.55-2.59 (m, 2H), 3.78 (s, 3H), 6.71-6.74 (m, 1H),6.88-6.93 (m, 2H). 3C NMR (100 MHz, CDC 3) 6 (ppm): 14.3, 22.8, 24.9, 29.3, 29.5, 29.6, 29.7, 29.8, , 30.1, 32.034.8, 35.0, 55.5, 110.5, 113.9, 124.6, 142.3, 142.8, 156.8,172.9.
Example 22. N-tert-butoxycarbonylglycine(2-tert-butyl-4 methoxyphenol)ester (XH2034) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonylglycine and 2-tert-butyl-4-methoxyphenol, the yield is 45%. 1H NMR (400 MHz, CDC 3) 6 (ppm).1.30 (s, 9H), 1.46 (s, 9H), 3.83 (s, 3H), 4.20 (s, 2H), 5.2 (br s, 1H), 6.71-6.73 (m, 1H),6.92-6.94 (m, 2H), 3C NMR (100 MHz, CDCl3 ) 6 (ppm): 28.2, 30.0, 34.4, 42.9, 55.4, 80.0, 110.4, 113.8, 124.2, 142.2, 155.5, 156.9, 169.5.
Example 23. (2-tert-butyl-4-methoxyphenol) 3-fluoro-4-chlorobenzoate (XH2035) The preparation method is the same as that of Example 3, via the condensation reaction of 3-fluoro-4-chlorobenzoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 78%. 1H NMR (400 MHz, CDCl3 ) 6 (ppm): 1.34 (s, 9H), 3.82 (s, 3H), 6.71 6.73 (m, 1H), 6.98-7.00 (m, 2H), 7.56-7.60 (m, 1H),7.96-7.97 (m, 2H). 3C NMR (100 MHz, CDCl3 ) : 30.2, 34.7, 55.6, 110.8, 114.1, 118.4, 124.6, 126.6, 130.4, 131.2, 142.6, 156.9, 157.3, 159.4,164.1.
Example 24. N-tert-butoxycarbonyltetrahydropyrrole, (2-tert-butyl-4 methoxyphenol) benzoheterocycle-3-formate (XH2036-1) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonyltetrahydropyrrole, benzoheterocycle-3-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 70%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 1.32 (s, 9H), 1.46 (s, 9H), 2.30-2.32 (m, 2H), 3.28-3.34 (m, 1H), 3.38-3.44 (m, 1H), 3.52-3.58 (m, 1H), 3.72-3.82 (m, 2H), 3.82 (s, 3H), 6.70-6.74 (m, 1H), 6.85-6.88 (m,1H),6.92-6.93 (m, 2H). 3C NMR (100 MHz, CDC 3 ) 6 (ppm): 28.4, 30.0, 34.5, 43.4, 45.1, 47.8, 55.5, 79.5, 110.5, 113.8, 124.3, 142.1, 142.5, 154.2, 156.9, 172.0.
Example 25. (2-tert-butyl-4-methoxyphenol) 3-cyanobenzoate (XH2036-2) The preparation method is the same as that of Example 3, via the condensation reaction of 3-cyanobenzoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 70%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.35 (s, 9H), 3.82 (s, 3H), 6.78-6.81 (m, 1H), 6.99-7.01 (m, 2H), 7.67-7.71 (t, J= 3.84Hz, 1H), 7.92-7.95 (m, 1H), 8.44-8.47 (m, 2H), 8.50 (s, 1H). 3C NMR (100 MHz, CDCl 3 ) (ppm): 30.1, 34.5, 55.6, 110.7, 6
113.3, 113.9, 117.7, 124.4, 129.8, 131.1, 133.7, 134.1, 136.5, 142.4, 157.2,163.9.
Example 26. (2-tert-butyl-4-methoxyphenol) N-tert butoxycarbonylalaninate(XH2036-3) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonylalanine and 2-tert-butyl-4-methoxyphenol, the yield is 37%. 1H NMR (400 MHz, CDC 3 ) 1.32 (s, 9H), 1.40 (s, 9H), 1.43 (d, 2H), 3.73 (s, 3H), 4.61 (m, 1H), 6.99-7.01 (m, 2H), 6.78-6.81 (m, 1H).
Example 27. (2-tert-butyl-4-methoxyphenol) 2-naphthoate (XH2036-4) The preparation method is the same as that of Example 3, via the condensation reaction of 2-naphthoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 77%. 1H
NMR (400 MHz, CDCl 3) 6 (ppM): 1.32 (s, 9H), 3.73 (s, 3H), 6.84 (m, 1H), 6.88-6.89 (m, 2H), 7.46-7.49 (m, 3H),7.82-7.85 (m, 4H). 3C NMR (100 MHz, CDC 3 ) (ppM): 30.0, 34.6, 42.4, 55.5, 110.6, 113.9, 124.5, 126.4, 127.6, 127.8, 128.6, 130.7, 131.7,
133.6, 142.4, 142.9, 157.0, 170.5.
Example 28. di(2-tert-butyl-4-methoxyphenol) malonate (XH2037) The preparation method is the same as that of Example 3, via the condensation reaction of malonicacid(5 mmol) and 2-tert-butyl-4-methoxyphenol(10 mmol), the yield is 70%. 1H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.35 (s, 18H), 3.80 (s, 6H), 3.88 (s, 2H), 6.75 (m, 2H), 6.94 (m, 2H),6.99-7.01 (m, 2H). 3C NMR (100 MHz, CDCl 3
) 5 (ppm). 30.2, 34.7, 42.6, 55.5, 110.8, 114.0, 124.4, 142.5, 142.6, 157.3,165.4.
Example 29. (2-tert-butyl-4-methoxyphenol) 3,6-dichloropyridazine-4 formate (XH2038-1) The preparation method is the same as that of Example 3, via the condensation reaction of 3,6-dichloropyridazine-4-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 77%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.36 (s, 9H), 3.82 (s, 3H), 6.76-6.79 (m, 1H), 6.97-7.02 (m, 2H),7.99 (s, 1H). 3C NMR (100 MHz, CDCl 3 ) o (ppm): 30.2, 34.7, 55.6, 110.8, 114.1, 124.4, 131.5, 137.8, 138.8, 142.3, 142.6, 157.5, 158.0, 161.4.
Example 30. (2-tert-butyl-4-methoxyphenol) 1-methylcyclopropyl formate (XH2038-2) The preparation method is the same as that of Example 1, by reacting 1 methylcyclopropyl formic acid and sulfoxide chloride, and then via the condensation reaction with 2-tert-butyl-4-methoxyphenol sodium, the yield is 87%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 0.83-0.85 (m, 2H), 1.33 (s, 9H), 1.40-1.42 (m, 2H), 1.46 (s, 3H), 3.78 (s, 3H), 6.72-6.73 (m, 1H), 6.84-6.87 (m, 1H), 6.90-6.92 (m, 1H), 13C NMR (100 MHz, CDCl 3) 6 (ppm): 17.3, 19.1, 19.7, 30.1, 34.6, 55.6, 110.6, 113.7, 124.7, 142.4, 143.2, 156.7,175.2.
Example 31. (2-tert-butyl-4-methoxyphenol) 2-indoleformate (XH2038-3) The preparation method is the same as that of Example 3, via the condensation reaction of 2-indoleformic acid and 2-tert-butyl-4-methoxyphenol, the yield is 67%. H NMR (400 MHz, CDCl3 ) 6 (ppm,): 1.33 (s, 3H), 3.77 (s, 3H), 7.08-7.11 (m, 1H), 7.16-7.20 (m, 1H), 7.32-7.40 (m, 2H), 7.43-7.44 (m, 1H), 7.74-7.77 (m, 1H),9.36 (s, 1H), 3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 30.1, 34.6, 55.5, 109.9, 110.5, 112.1, 113.9, 121.0, 122.7, 124.6, 125.8, 126.8, 127.4, 137.3, 142.3, 142.7, 157.0, 161.3.
Example 32. (2-tert-butyl-4-methoxyphenol) 2-chloro-3-picolinate
(XH2038-4) The preparation method is the same as that of Example 3, via the condensation reaction of 2-chloro-3-picolinic acid and 2-tert-butyl-4-methoxyphenol, the yield is 87%. 'H NMR (400 MHz, CDCl3) (ppm).' 1.34 (s, 9H), 3.83 (s, 3H), 6.79-6.82 (m, 1H), 6.98-6.99 (m, 1H), 7.05-7.07 (m, 1H), 7.43 (m, 1H), 8.37-8.39 (m, 1H),8.61 (s, 1H). 3C NMR (100 MHz, CDCl 3 ) (ppm): 30.2, 34.7, 55.6, 110.9, 114.1, 122.4, 6
124.5, 126.7, 140.5, 142.5, 142.6, 150.7, 152.5, 157.4, 163.7.
Example 33. (2-tert-butyl-4-methoxyphenol) 2-thiopheneacetate (XH2038-5) The preparation method is the same as that of Example 3, via the condensation reaction of 2-thiopheneacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 70%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.27 (s, 9H), 3.78 (s, 3H), 4.10 (s, 2H), 6.70-6.73 (m, 1H), 6.87 (m, 1H), 6.90-.92 (m, 2H), 6.98-7.07 (m, 1H), 7.04-7.06 (m, 2H),7.24 (m, 1H). 3C NMR (100 MHz, CDC 3 )c (ppn): 30.1, 34.6,36.1, 55.5, 110.6, 113.9, 124.4, 125.4, 127.1, 127.5, 134.2, 142.4, 142.8, 157.0, 169.4.
Example 34. (2-tert-butyl-4-methoxyphenol) 3-(4-methylphenyl)-propionate (XH2039-1) The preparation method is the same as that of Example 3, via the condensation reaction of 3-(4-methylphenyl)-propionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 65%. 1H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.29 (s, 9H), 2.32 (s, 3H), 2.88 2.90 (t, J= 8.2 Hz, 2H), 3.03-3.05 (t, J= 8.2 Hz, 2H), 3.78 (s, 3H), 6.69-6.72 (m, 1H), 6.81-6.84 (m, 1H), 6.90-.92 (m, 1H), 7.12-7.15 (m, 4H). 3C NMR (100 MHz, CDC 3 ) (ppm,): 21.0, 30.3, 34.5, 36.6, 55.4, 110.4, 113.7, 124.4, 128.3, 129.2, 135.8, 137.0, 142.2, 142.6, 156.7, 171.8.
Example 35. (2-tert-butyl-4-methoxyphenol) 2-phenyl propionate (XH2039 3) The preparation method is the same as that of Example 3,via the condensation reaction of 2-phenylpropionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 65%. 'H NMR (400 MHz, CDC 3) 8(ppm): 1.16 (s, 9H), 1.63-1.67 (d, J =8.8 Hz, 3H), 3.76 (s, 3H), 3.93-3.97 (q, J= 8.8 Hz, 1H), 6.68-6.70 (m, 2H), 6.75-6.77 (m, 1H), 6.87-6.88 (m, 1H),7.20-7.45 (m, 5H). 3C NMR (100 MHz, CDC 3 ) 6 (ppm): 18.1, 29.7, 34.4, 46.1, 55.4, 110.4, 113.6, 124.1, 127.4, 127.8, 128.7, 139.5, 142.3, 142.9, 156.7, 173.3.
Example 36. (2-tert-butyl-4-methoxyphenol) 2-fluoropropionate (XH2039-4)
The preparation method is the same as that of Example 3,via the condensation reaction of 2-fluoropropionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 60%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.33 (s, 9H), 1.72-1.80 (m, 3H), 3.80 (s, 3H), 5.19-5.31 (m, 1H), 6.73-6.76 (m, 1H),6.92-6.95 (m, 2H). 3C NMR (100 MHz, CDC 3 ) ((ppm): 18.0, 18.2, 29.9, 34.6, 55.4, 84.9, 86.7, 110.5, 113.9, 123.9, 142.0, 142.3, 157.1, 169.4.
Example 37. (2-tert-butyl-4-methoxyphenol) cyclohexylacetate (XH2039-5) The preparation method is the same as that of Example 3,via the condensation reaction of cyclohexylacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 68%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.00-1.20 (m, 3H), 1.20-1.40 (m, 11H), 1.63 1.76 (m, 3H), 1.90-2.00 (m, 1H), 1.83-1.87 (m, 2H), 2.44-2.46 (m, 2H), 3.77 (s, 3H), 6.70-6.73 (m, 1H),6.88-6.92 (m, 2H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 26.0, 26.1, 30.0, 33.1, 34.5, 34.6, 42.6, 55.4, 110.4, 113.7, 124.5, 142.2, 142.7, 156.6, 171.9.
Example 38. (2-tert-butyl-4-methoxyphenol) cyclopentanecarboxylate (XH2039-6) The preparation method is the same as that of Example 3,via the condensation reaction of cyclopentyl formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 78%. 'H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.33 (s, 9H), 1.63-1.70 (m, 2H), 1.74 1.82 (m, 2H), 1.93-2.07 (m, 4H), 3.78 (s, 3H), 6.71-6.73 (m, 1H), 6.86-6.88 (d, J= 8.8Hz, 1H), 6.91-6.92 (d, J= 2.8 Hz, 1H). 3C NMR (100 MHz, CDCl 3) 6 (ppm). 25.7, 29.9, 34.5, 44.4, 55.4, 110.4, 113.6, 124.4, 142.2, 142.9, 156.6, 175.6.
Example 39. (2-tert-butyl-4-methoxyphenol) adamantaneacetate (XH2040-1) The preparation method is the same as that of Example 3, via the condensation reaction of adamantaneacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 70%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 1.32 (s, 9H), 1.66-1.76 (m, 12H), 2.01 (br s, 3H), 2.32 (s, 2H), 3.79 (s, 3H), 6.71-6.74 (m, 1H), 6.91-6.94 (m, 2H). 13C
NMR (100 MHz, CDC 3 ) 6 (ppm): 28.7, 30.1, 33.3, 34.6, 36.8, 42.6, 49.2, 55.6, 110.5, 113.8, 124.6, 142.4, 142.7, 156.8, 170.8.
Example 40. (2-tert-butyl-4-methoxyphenol) cyclopropylacetate (XH2040-2) The preparation method is the same as that of Example 3,via the condensation reaction of cyclopropylacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 73%. 'H NMR (400 MHz, CDCl 3 ) 6 (ppm): 0.25-0.29 (m, 2H), 0.61-0.66 (m, 2H),
1.19-1.23 (m, 1H), 1.33 (s, 9H), 2.47-2.49 (d, J= 7.2 Hz, 2H), 3.79 (s, 3H), 6.72 6.75 (m, 1H), 6.91-6.93 (m, 2H). "C NMR (100 MHz, CDCl 3 ) 6 (ppm). 4.77, 6.92, 30.1, 40.2, 55.6, 110.6, 113.9, 124.7, 142.4, 142.9, 156.9, 172.2.
Example 41. (2-tert-butyl-4-methoxyphenol) N-tert butoxycarbonylpiperidine-4-formate(XH2040-3) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonylpiperidine-4-formic acid and 2-tert-butyl-4 methoxyphenol, the yield is 73%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.32 (s, 9H), 1.47 (s, 9H), 1.73-1.84 (m, 2H), 2.05-2.10 (m, 2H), 2.66-2.73 (m, 1H), 2.85-2.93 (m, 2H), 3.79 (s, 3H), 4.11-4.16 (m, 2H), 6.71-6.74 (m, 1H), 6.82-6.84 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J= 3.2 Hz, 1H). NMR (100 MHz, CDC 3 ) 6 (ppm).: 28.0, 3C
28.5, 30.1, 34.7, 41.8, 43.4, 55.6, 79.8, 110.7, 113.8, 124.5, 142.3, 142.8, 154.7, 156.9, 173.7.
Example 42. (2-tert-butyl-4-methoxyphenol) octanoate (XH2040-4) The preparation method is the same as that of Example 3, via the condensation reaction of octanoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 63%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 0.87-0.91 (m, 3H), 1.27-1.43 (m, 18H), 1.73-1.81 (m, 2H), 2.55-2.59 (t, J= 7.6 Hz, 2H), 6.71-6.74 (m, 1H), 6.88-6.90 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J= 3.2 Hz, 1H). 3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 14.2, 22.7, 24.9, 29.0, 29.3, 30.1, 31.8, 34.7, 35.0, 55.6, 110.5, 113.8, 124.6, 142.3, 142.8, 156.8, 172.9.
Example 43. (2-tert-butyl-4-methoxyphenol) 7-oxooctanoate (XH2040-5) The preparation method is the same as that of Example 3, via the condensation reaction of 7-oxooctanoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 60%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.30-1.44 (m, 13H), 1.60-1.66 (m, 2H), 1.74 1.80 (m, 2H), 2.16 (s, 3H), 2.45-2.49 (t, J= 7.2 Hz, 2H), 2.57-2.60 (t, J= 7.6 Hz, 2H), 3.79 (s, 3H), 6.71-6.74 (m, 1H), 6.88-6.90 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J = 3.2 Hz, 1H). 3C NMR (100 MHz, CDCl 3) (ppm): 23.4, 24.6, 28.7, 29.5, 30.1, 6
34.6, 34.7, 43.5, 55.6, 110.6, 111.8, 124.6, 142.3, 142.7, 156.8, 172.6, 209.0.
Example 44. (2-tert-butyl-4-methoxyphenol) cyclohexene-2-carboxylate (XH2041-1) The preparation method is the same as that of Example 3, via the condensation reaction of cyclohexene-2-carboxylic acid and 2-tert-butyl-4-methoxyphenol, the yield is 57%. 1H NMR (400 MHz, CDCl3) 6 (ppm). 1.31 (s, 9H), 2.78-2.86 (m, 4H), 3.36-3.41 (m, 1H), 3.79 (s, 3H), 5.72 (s, 2H), 6.71-6.74 (m, 1H), 6.88-6.90 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J= 3.2 Hz, 1H). 3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 30.1, 34.6, 36.2, 42.4, 55.6, 110.6, 113.8, 124.5, 129.1, 142.3, 143.1, 156.8, 175.1.
Example 45. (2-tert-butyl-4-methoxyphenol) 2,4,5-trifluorophenylacetate (XH2041-2) The preparation method is the same as that of Example 3, via the condensation reaction of 2,4,5-trifluorophenylacetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 77%. 1H NMR (400 MHz, CDC 3) 6 (ppm): 1.27 (s, 9H), 3.78 (s, 3H), 3.87 (s, 2H), 6.71-6.74 (m, 1H), 6.88-6.91 (m, 2H), 6.95-7.01 (m, 1H), 7.19-7.25 (m, 1H).3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 29.8, 34.4, 55.4, 105.4, 105.6, 105.7, 105.9, 110.5, 113.8, 119.1, 119.3, 124.2, 142.2, 142.5, 157.0, 168.7.
Example 46. (2-tert-butyl-4-methoxyphenol) 2-bromo-5-iodo benzoate (XH2041-3) The preparation method is the same as that of Example 3, via the condensation reaction of 2-bromo-5-iodobenzoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 87%. 'H NMR (400 MHz, CDC 3) 6 (ppm): 1.34 (s, 9H), 3.82 (s, 3H), 6.78-6.80 (m, 1H), 6.97-6.98 (d, J= 2.8 Hz, 1H), 7.05-7.07 (d, J= 8.8 Hz, 1H), 7.45-7.47 (d, J = 8.4 Hz, 1H), 7.69-7.71 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 8.28 (d, J= 2.0 Hz, 1H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 30.4, 34.8, 55.7, 92.1, 110.9, 114.2, 122.4, 124.5, 133.7, 136.5, 140.3, 142.1, 142.8, 157.4, 164.1.
Example 47. (2-tert-butyl-4-methoxyphenol) 2-fluoro-4-nitryl benzoate (XH2041-4) The preparation method is the same as that of Example 3, via the condensation reaction of 2-fluoro-4-nitrylbenzoic acid and 2-tert-butyl-4-methoxyphenol, the yield is 85%. 'H NMR (400 MHz, CDCl3) 6 (ppM): 1.32 (s, 9H), 3.83 (s, 3H), 6.78-6.81 (dd, J1 = 8.4Hz, J2 = 3.2 Hz, 1H), 6.98-6.99 (d, J= 3.2 Hz, 1H), 7.02-7.05 (d, J= 8.4 Hz, 1H), 8.09-8.12 (dd, J1 = 9.6 Hz, J2 = 2.0 Hz, 1H), 8.15-8.18 (m, 1H), 8.30 8.34 (m, 1H). 3C NMR (100 MHz, CDCl 3) 6 (ppm). 30.0, 34.5, 55.5, 110.7, 113.1, 113.4, 114.0, 119.1, 123.9, 124.0, 124.3, 133.7, 142.2, 142.4, 151.3, 157.3, 160.3, 162.0, 163.0.
Example 48. (2-tert-butyl-4-methoxyphenol) N-tert butoxycarbonylpiperidine-3-formate(XH2041-5)
The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonylpiperidine-3-formic acid and 2-tert-butyl-4 methoxyphenol, the yield is 65%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.32 (s, 9H), 1.47 (s, 9H), 1.50-1.67 (m, 2H), 1.76-1.82 (m, 2H), 2.22-2.26 (m, 1H), 2.67-2.73 (m, 1H), 2.82-2.89 (m, 1H), 3.10-3.16 (m, 1H), 3.79 (s, 3H), 3.98-4.01 (m, 1H), 4.33 (br s, 1H), 6.71-6.74 (dd, J1= 8.8 Hz, J2 = 2.8 Hz,1H), 6.83-6.85 (d, J= 8.8 Hz, 1H), 6.91-6.92 (d, J= 2.8 Hz, 1H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 14.1, 24.2, 27.2, 28.3, 29.4, 30.1, 34.5, 41.8, 55.4, 79.8, 110.5, 113.7, 124.4, 142.2, 142.6, 154.6, 156.8, 172.4.
Example 49. di(2-tert-butyl-4-methoxyphenol) p-phenylenediacetate (XH2042) The preparation method is the same as that of Example 3, via the condensation reaction of p-phenylenediaceticacid(5 mmol) and 2-tert-butyl-4-methoxyphenol(10 mmol), the yield is 65%. 'H NMR (400 MHz, CDCl 3) 6 (ppm): 1.23 (s, 18H), 3.74 (s, 6H), 6.67 - 6.71(dd, J1= 8.8 Hz, J2= 3.2 Hz, 2H), 6.83-6.86 (d, J= 8.8 Hz, 2H), 6.89-6.90 (d, J= 3.2 Hz, 2H), 7.39 (s, 4H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 30.1, 34.6, 41.9, 55.6, 110.7, 114.0, 124.6, 130.1, 132.5, 142.5, 142.9, 157.1, 170.5.
Example 50. (2-tert-butyl-4-methoxyphenol) 4-benzoyl butyrate (XH2043-1) The preparation method is the same as that of Example 3, via the condensation reaction of 4-benzoylbutyric acid and 2-tert-butyl-4-methoxyphenol, the yield is 75%. H NMR (400 MHz, CDC 3) 6 (ppm). 1.32 (s, 9H), 2.20-2.23 (m, 2H), 2.71-2.75 (t, J = 8.8 Hz, 2H), 3.14-3.17 (t, J= 7.0 Hz, 2H), 3.79 (s, 3H), 6.72-6.75 (m, 1H), 6.91 6.93 (m, 2H), 7.44-7.49 (m, 2H), 7.55-7.59 (m, 1H), 7.97-7.99 (m, 2H). 3C NMR (100 MHz, CDC 3) 6 (ppm). 19.4, 30.2, 34.1, 34.7, 37.6, 55.7, 110.7, 114.0, 124.7, 128.2, 128.9, 133.4, 136.9, 142.4, 142.8, 157.0, 172.5, 199.6.
Example 51. (2-tert-butyl-4-methoxyphenol) 3,5-dimethoxy phenylacrylate (XH2043-2) The preparation method is the same as that of Example 3, via the condensation reaction of 3,5-dimethoxyphenylacrylic acid and 2-tert-butyl-4-methoxyphenol, the yield is 60%. 1H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.35 (s, 9H), 3.81 (s, 3H), 6.53 6.54 (t, J=2.3 Hz, 1H), 6.61-6.65 (d, J= 16Hz, 1H), 6.73-6.78 (m, 3H), 6.95-7.00 (m, 2H), 7.77-7.81 (d, J= 16Hz, 1H). 3C NMR (100 MHz, CDCl 3) 6 (ppm): 30.3, 34.8, 55.7, 103.1, 106.4, 110.7, 114.0, 118.4, 124.8, 136.2, 142.7, 146.8, 157.1, 161.3, 166.2.
Example 52. (2-tert-butyl-4-methoxyphenol) 4-chloropyridine-2-formate (XH2043-3) The preparation method is the same as that of Example 3, via the condensation reaction of 4-chloropyridine-2-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 65%. 1H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.36 (s, 9H), 3.82 (s, 3H), 6.78 6.81 (dd, J1 = 9.2 Hz, J2 = 3.0 Hz, 1H), 6.98-6.99 (d, J= 3.0 Hz, 1H), 7.04-7.06 (d, J = 9.2Hz, 1H), 7.56-7.58 (dd, J1= 5.2 Hz, J2 = 2.3Hz, 1H), 8.27-8.28 (m, 1H), 8.75-8.76 (d, J= 5.2 Hz, 1H). 3C NMR (100 MHz, CDC 3) (ppmi): 30.4, 34.9, 55.7, 6
110.9, 114.2, 124.6, 126.4, 127.7, 142.8, 145.8, 149.3, 151.3, 157.4, 163.7.
Example 53. (2-tert-butyl-4-methoxyphenol) N-methylpiperidine-3-formate (XH2043-4) The preparation method is the same as that of Example 3, via the condensation reaction of N-methylpiperidine-3-formic acid and 2-tert-butyl-4-methoxyphenol, the yield is 60%. 1H NMR (400 MHz, CDCl 3 ) 5 (pp):1.34 (s, 9H), 1.51-1.61 (m, 1H), 1.65-1.74 (m, 1H), 1.80-1.85 (m, 1H), 1.99-2.05 (m, 1H), 2.13-2.18 (m, 1H), 2.24 2.31 (m, 1H), 2.34 (s, 3H), 2.79-2.92 (m, 2H), 3.14-3.16 (br d, 1H), 3.78 (s, 3H), 6.70-6.74 (dd, J1 = 8.4 Hz, J2= 3.2 Hz, 1H), 6.84-6.86 (d, J= 8.4 Hz, 1H).3C NMR (100 MHz, CDC 3 ) 6 (ppm): 24.6, 26.3, 29.9, 34.5, 42.3, 46.4, 55.4, 55.5, 57.1, 110.5, 113.7, 124.4, 142.2, 142.6, 156.7, 172.9.
Example 54. (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonyl-6 amino pentanoate (XH2043-5) The preparation method is the same as that of Example 3, via the condensation reaction of N-tert-butoxycarbonyl-6-amino pentanoic acid and 2-tert-butyl-4 methoxyphenol, the yield is 60%. 1H NMR (400 MHz, CDCl 3 ) 6 (ppm): 1.32 (s, 9H), 1.45 (s, 9H), 1.57-1.65 (m, 2H), 1.75-1.83 (m, 2H), 2.59 (t, J= 7.6 Hz, 2H), 3.16-3.19 (t, J= 6.8 Hz, 2H), 3.79 (s, 3H), 6.71-6.74 (dd, J1= 8.8 Hz, J2= 2.8 Hz, 1H), 6.87-6.89 (d, J= 8.8 Hz, 1H), 6.92-6.93 (d, J = 2.8 Hz, 1H). 3C NMR (100 MHz, CDCl 3 ) (ppm): 22.1, 28.6, 29.8, 30.2, 34.6, 34.8, 40.4, 55.7, 110.7, 114.0, 6
124.7, 142.5, 142.9, 156.2, 157.0, 172.6.
Example 55. (2-tert-butyl-4-methoxyphenol) 3,3,3-trifluoropropionate (XH2044-1) The preparation method is the same as that of Example 3, via the condensation reaction of 3,3,3-trifluoropropionic acid and 2-tert-butyl-4-methoxyphenol, the yield is 60%. 'H NMR (400 MHz, CDC 3 ) 6 (ppm): 1.33 (s, 9H), 3.41-3.48 (q, J= 19.9 Hz, 2H), 3.79 (s, 3H), 6.72-6.75 (m, 1H), 6.91-6.94 (m, 2H). 3C NMR (100 MHz, CDCl3 ) 6 (ppm):30.2, 34.8, 40.3, 55.7, 110.9, 114.2, 124.4, 142.5, 157.5, 163.5.
Example 56. (2-tert-butyl-4-methoxyphenol) morpholin-4-yl acetate (XH2044-2) The preparation method is the same as that of Example 3, via the condensation reaction of morpholin-4-yl acetic acid and 2-tert-butyl-4-methoxyphenol, the yield is 68%. 'H NMR (400 MHz, CDCl3 ) 1.30 (s, 9H), 2.65-2.68 (t, J = 4.4 Hz, 4H), 6:
3.47 (s, 2H), 3.75-3.79 (m, 7H), 6.70-6.73 (m, 1H), 6.89-6.92 (m, 2H). 3C NMR (100 MHz, CDCl 3 ) 5 (pprm): 30.3, 34.7, 53.5, 55.7, 60.2, 67.0, 110.7, 114.1, 124.6, 142.4, 157.1, 169.2.
Example 57. (2-tert-butyl-4-methoxyphenol) 3-(3,5-di-tert-butyl-4-hydroxy phenyl)propionate (XH2045-2) The preparation method is the same as that of Example 3, via the condensation reaction of 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)propionic acid and 2-tert-butyl-4 methoxyphenol, the yield is 68%. 1 H NMR (400 MHz, CDCl 3 )c (ppm): 1.29 (s, 9H), 1.45 (s, 18H), 2.86-2.90 (m, 2H), 2.99-3.03 (m, 2H), 3.78 (s, 3H), 5.10 (br s, 1H), 6.69-6.72 (m, 1H), 6.80-6.83 (d, J= 8.8 Hz, 1H), 6.90-6.91 (d, J= 3.0 Hz, 1H), 7.06 (s, 2H). 3C NMR (100 MHz, CDCl3 ) 8 (ppm): 30.0, 30.2, 30.8, 34.2, 34.5, 37.0, 55.4, 110.4, 113.7, 124.5, 124.9, 130.7, 135.9, 142.2, 142.7, 152.3, 156.7, 172.1.
Example 58. di(2-tert-butyl-4-methoxyphenol) adipate (XH2046-3) The preparation method is the same as that of Example 3, via the condensation reaction of adipicacid (5 mmol) and 2-tert-butyl-4-methoxyphenol (10 mmol), the yield is 65%. 1H NMR (400 MHz, CDCl3 ) 6 (ppm): 1.32 (s, 18H), 1.89-1.93 (m, 4H), 2.64-2.68 (m, 4H), 3.79 (s, 6H), 6.71-6.74 (m, 2H), 6.89-6.93 (m, 4H). 3C NMR (100 MHz, CDCl 3 ) 6 (ppm): 24.3, 30.1, 34.6, 55.6, 110.6, 113.9, 124.6, 142.4, 142.7, 156.9, 172.3.
Example 59. (2-tert-butyl-4-methoxyphenol-oxyl) methyl carbonate isopropyl ester (XJP2005) Dissolving 2-tert-butyl-4-methoxyphenol (5 mmol) in tetrahydrofuran (15 mL), and dropwise adding to the solution of sodium hydride (5.5 mmol)/tetrahydrofuran (10 mL), thereafter, stirring for 30 minutes. Dropwise adding chloromethyl isopropyl carbonate (5 mmol), and then reacting for 24 hours at room temperature.
The colourless oily matter is obtained through purification by column chromatography (ethyl acetate: petroleum ether=1: 9), the yield is 75%. 'H-NMR (CDC 3) 5 (ppm): (ppm) 1.32 (s, 9H), 1.35 (d, J= 6.4 Hz, 6H), 3.78 (s, 3H), 4.31 (in, 1H), 5.26 (s, 2H), 6.71-6.74 (in, 1H), 6.90-6.91 (d, J= 3.0 Hz, 1H), 6.96-6.97 (d, J = 8.6 Hz, 1H).
Example 60. N-(2-tert-butyl-4-methoxyphenol-oxycarbonyl)glycine ethyl ester (XJP2006) Dissolving glycine ethyl ester (5.10 mmol) in 100 mL dichloromethane, adding saturated sodium hydrocarbonate solution, stirring in ice-water bath for 5 min. Then adding triphosgene (530 mg, 1.786 mmol), stirring intensely for 15 min. The D-aspartic acid benzyl ester isocyanate (1-1) is obtained by extracting with dichloromethane for four times, drying with anhydrous Na 2 SO 4 for 1h, and concentrating to dryness by distillation under reduced pressure. Adding 2-tert butyl-4-methoxyphenol (1.28 mmol) to 100 mL anhydrous tetrahydrofuran, adding triethylamine (386 mg, 3.83 mmol), stirring for 30 min at room temperature, dissolving the above prepared isocyanate (1-1) with 2 mL dichloromethane, adding to the reaction liquid, raising the temperature to 40°C, stirring for overnight. Quenched the reaction, directly mixed with silica gel, and then evaporated to dryness by distillation, purifying by silica gel column chromatography (ethyl acetate : petroleum ether=1: 3). The colourless oily matter is obtained, the yield is 56.8%. 'H-NMR (CDCl 3) 6 (ppm): (ppm) 1.28-1.32 (t, J= 7.0 Hz, 3H ), 1.34 (s, 9H), 3.79 (s, 3H), 4.06-4.08 (d, J = 5.3 Hz, 2H), 4.22-4.28 (q, J = 7.0 Hz, 2H), 5.53-5.56 (t, J= 5.3 Hz, 1H), 6.71-6.74 (in, 1H), 6.90-6.91 (d, J= 3.0 Hz, 1H), 6.96-6.97 (d, J= 8.6 Hz, 1H).
Example 61. 2-(2-tert-butyl-4-methoxyphenoxy) ethyl acetate (XJP1005) Dissolving 2-tert-butyl-4-methoxyphenol (5 mmol) in tetrahydrofuran(15 mL), then dropwise adding to the solution of sodium hydride (5.5 mmol)/tetrahydrofuran(10 mL), then stirring for 30minutes. Dropwise adding ethyl bromoacetate (5 mmol), and then reacting for 24 hours at room temperature. The colourless oily matter is obtained through purification by column chromatography (ethyl acetate:petroleum ether =1: 9), the yield is 75%. 'H-NMR (CDCl3 ) 6: (ppm) 1.28-1.32 (t, J= 7.2 Hz, 3H), 1.40 (s, 9H), 3.77 (s, 3H), 4.24-4.30 (q, J= 7.2 Hz, 2H), 4.59 (s, 2H), 6.65-6.66 (in, 2H), 6.88-6.91 (in, 1H).
Example 62. preparation of (2-tert-butyl-4-methoxyphenol) (N benzyl)carbamate (ZXY1025-2) Dissolving 2-tert-butyl-4-methoxyphenol (0.9g, 5 mmol) in dichloromethane (15 mL), adding triethylamine (0.1 mL), dropwise adding the solution of benzyl isocyanate (5 mmol)/dichloromethane (10 mL), then stirring and reacting for 4 10hours, washing with water, and white solid can be obtained from column chromatography, the yield is 85%. 1H-NMR (CDC 3 ) 6 (ppm) 1.32 (s, 3H), 3.78 (s, 3H), 4.47-4.48 (d, J= 2.2 Hz, 2H), 5.32-5.34 (br t, J =2.2 Hz, 1H), 6.71-6.74 (m, 1H), 6.89-6.90 (d, J= 3.2 Hz, 1H), 6.98-7.01 (d, J= 8.4 Hz, 1H), 7.30-7.38 (m, 5H).
Example 63. preparation of (2-tert-butyl-4-methoxyphenol) (N-n butyl)carbamate(ZXY1025-3) The preparation method is the same as that of Example 62, which is prepared from the reaction of 2-tert-butyl-4-methoxyphenol and butyl isocyanate, the yield is 90%. 'H-NMR (CDC 3) 6(ppm) 0.92-0.95 (t, J= 8.0 Hz, 3H), 1.32-1.41 (m, 11H), 1.51-1.58 (m, 2H), 3.25-3.30 (q, J= 6.8 Hz, 2H), 3.78 (s, 3H), 4.99 (br t, 1H), 6.70 6.73 (m, 1H), 6.88-6.89 (d, J= 3.2 Hz, 1H), 6.94-6.97 (d, J= 8.8 Hz, 1H).
Example 64. (2-tert-butyl-4-methoxyphenol) (N-isopropyl)carbamate (ZXY1025-4) The preparation method is the same as that of Example 62, and the yield is 85%. 1H-NMR (CDC 3 ) 6(ppm) 1.21-1.23 (d, J= 6.4 Hz, 6H), 1.32 (s, 9H), 3.78 (s, 3H), 3.88-3.93 (m, 1H), 4.82-4.84 (br d, J= 8.0 Hz, 1H), 6.70-6.73 (m, 1H), 6.88-6.89 (d, J= 3.2 Hz, 1H), 6.94-6.97 (d, J= 8.8 Hz, 1H).
Example 65. (2-tert-butyl-4-methoxyphenol) (N-cyclohexyl)carbamate (ZXY1025-5) The preparation method is the same as that of Example 62, and the yield is 87%. H-NMR (CDC 3 ) 6 (ppm) 1.13-1.25 (m, 2H), 1.32-1.42 (m, 12 H), 1.60-1.64 (m, 1H), 1.72-1.75 (m, 2H), 1.99-2.03 (m, 2H), 3.54-3.61 (m, 1H), 3.78 (s, 3H), 4.87 4.89 (d, J= 8.4 Hz, 1H), 6.70-6.73 (m, 1H), 6.88-6.89 (d, J= 2.0 Hz, 1H), 6.95-6.97 (d, J= 8.4 Hz, 1H).
Example 66. (2-tert-butyl-4-methoxyphenol) (N-phenethyl)carbamate (ZXY1025-6) The preparation method is the same as that of Example 62, and the yield is 87%. 1H-NMR (CDCl3 ) 6 (ppm) 1.30 (s, 9H), 2.87-2.90 (t, J= 6.4 Hz, 2H), 3.52-3.57 (m, 2H), 3.77 (s, 3H), 5.03 (m, 1H), 6.69-6.72 (m, 1H), 6.88-6.94 (m, 2H), 7.22-7.25 (m,
3H), 7.30-7.34 (m, 2H).
Example 67. pivaloyl(2-tert-butyl-4-methoxyphenol-oxyl) methyl ester (XJP1041) Dissolving 2-tert-butyl-4-methoxyphenol (5 mmol) in tetrahydrofuran (15 mL), then dropwise adding the solution of sodium hydride (5.5 mmol)/tetrahydrofuran (10 mL), and then stirring for 30 minutes. Dropwise adding pivaloy chloride methyl ester (5 mmol), and then reacting for 24 hours at room temperature. The off-white solid can be obtained by purifying with column chromatography (ethyl acetate : petroleum ether =1:9), the yield is 75%. 'H-NMR (CDCl) 6 (ppm) 1.24 (s, 9H), 1.32 (s, 9H), 3.78 (s, 3H), 5.30 (s, 2H), 6.69-6.72 (m, 1H), 6.88-6.94 (m, 2H).
Example 68. Evaluation the release effect of the compound in vitro 1.Analysis conditions Mobile phase: gradient elution; A: water; B: methanol; Chromatographic column: CAPCEL PAK MF PH-1; Detecting instrument: TQ-S; ion source: APCI; ion detection mode: MRM; 2.Releasing tests of target compound in PBS (pH=7.4) Dissolving a certain amount of the compound in the PBS, vortex blending, dividing into 10 parts equally based on 0.3 mL per part. Incubating at 37°C, taking sample at different time(Oh, 1h, 2h, 6h, 12h, 24h and 48h, etc.), followed with HPLC detection. Calculating the release rate of the drugs by the peak area of the target compound at Oh as a standard. Comparing the peak area of the compounds at other time points with the standard peak area. The experimental results show that the compounds of all the examples remain stable in the aqueous solution, and no BHA was detected. 3.Release experiment of target compound in human plasma Dissolving the target compound with DMSO, then diluting to 5pg/mL with the normal saline of 0.9 %. The human blank plasma after subpackage is preserved at 70°C, unfreezing in a refrigerator at 4°C when used. Take 20pL of the blank plasma, adding 20 pL of the target coumpound solution as above formulated, vortexing for 15 s, and left it in the water bath at 37 °C. Taking samples at the time points of 5 min, 20 min, 40 min, 1.5h, 3h, 6h and 9h, respectively, with three parallel samples for each time point. Adding 100 tL methanol to the samples at different time points of the water bath, precipitating protein, vortexing for1 min, centrifugating at low temperature in 13000 r• min-i for 15 min. Take the supernatant and inject 10pL for detection.
The results show that all the compound can release BHA, however, the releasing rate and duration time are different, as shown by figure 3.
Example 69. Metabolism experiments of the drugs in the rats in vivo 1. Experimental method Intragastric administrating a drug to the rats weighed 180-200g; the administration dosage: 100 mg/kg; adminstratin solution: 2.5 mg/ mL (lyase is corn oil); fasting for 12h before administration, with free drinking. Taking 20pL plasma of the rat at different blood collecting points. Adding 20tL deionized water followed with 100pL methanol, vortexing for 1 min, contrifugating for 15 min at 13000rpm. taking 10pL for LC-MS/MSanalysis. Totally, there are 11 blood collecting points: 0 min, 5 min, 20 min, 40 min, lh, 1.5h, 2h, 4h, 8h, 12h, 24h. 2. Analysis for testing conditions Mobile phase: A: water; B: methanol, (binary gradient); Elution conditions are shown by table 1: Table 1 Elution conditions time(min) flow rate(1 min mL/ A B 0 1 65 35 8 1 30 70 8.1 1 0 100 9 1 0 100 9.1 1 65 35 12 1 65 35 Ion source: APCI; ion detection mode: MRM. 3. Experimental results of representative compounds According to the experimental results of BHA released in plasma, the compounds with quality metabolic characteristics are selected in the present invention to ensure the metabolic experiments in vivo. The results show that the prodrugs in the present invention can continuously release BHA in vivo (figure 4), and the plasma concentration can remain stable for 12h.
Example 70. Test for cytotoxic activity The toxicity of compounds is detected with MTS method in the immortalized mice bone marrowmacrophages (IBMM), mice embryonic fibroblast (NIH3t3) and humanized embryonic nephrocyte. The results show that, the cytotoxicity of the compounds in the examples are all mild, with IC5 0 thereof above 20mmol, especially the toxicity to macrophages is lower, the security window of the drugs for adjusting differentiation of macrophages is larger (SI>1000). It also can be proved that the anti-tumor effect of the compounds in the examples is irrelevant with the cytotoxicity, which is completely different from the mechanism of the existing anti tumor drugs. The results are shown in table 2 as follows.
Table 2. Experimental results of cytotoxicity of some of the compounds
compound IC5 o(mM) code IBMM cell NIH3T3 cell HEK293 cell BHA 218 267 325 XH2005 439 87.5 82 XH2006 443 21.0 118 XH2010 175 186. 207 XH2011 119 32.6 311 XH2015 147 194. 109 XH2016 148 18.6 65 XH2017 560 22.9 8 XH2018 130 333 386 XH2019 24 47.6 37 XH2020 >700 689 >700 XH2021 419 281 >700 XH2022 141 238 >700 XH2023 6.5 65 30 XH2024 126 228 >700 XH2025 >700 >700 282 XH2026 >700 >700 >700 XH2027 93 96 177 XH2028 156 133 661 XH2029 205 >700 239 XH2030 229 175 151 XH2031 218 124 83 XH2033 652 >700 >700 XH2034 192 237 190 XH2035 202 82 160 XH2036-1 225 152 160 XH2036-2 189 205 182 XH2036-4 230 232 253 XH2037 247 256 251 XH2038-1 222 236 330 XH2038-2 131 195 257 XH2038-3 263 517 205 XH2038-4 122 155 141 XH2038-5 202 146 266 XH2039-1 166 223 271 XH2039-2 159 248 125 XH2039-3 48 174 188 XH2039-4 161 233 294 XH2039-5 67 106 87 XH2039-6 171 229 136 XH2040-1 55 132 129 XH2040-2 202 232 237 XH2040-3 115 151 287 XH2040-4 198 366 283 XH2040-5 249 217 342 XH2041-1 180 140 218 XH2041-2 156 260 349 XH2041-3 60 139 279 XH2041-4 224 173 >700 XH2041-5 51 171 67
XH2042 388 >700 61 XH2043-1 409 >700 279 XH2043-2 100 365 >700 XH2043-3 331 106 >700 XH2043-4 146 132 >700 XH2043-5 97 157 377 XH2044-1 >700 353 206 XH2044-2 561 >700 125 XH2045-2 154 142 111 XH2046-3 352 >700 >700 XJP2006 92 300 176 XJP2005 309 171 >700
Example 71.Experiments of acute toxicity in mice 1.Experimental method Detecting the acute toxicity of some of the compounds by using up-down method. Intragastric administrating a drug to the mice of 20-22g; lyase is corn oil, fasting for 12h before administration, with free drinking. 2.Experimental results The results are shown in table 3, which identified with the experimental results of cytotoxicity. The acute toxicity of the representive compounds XH2006, XH2010, XH2011 and XH2044-2 prepared by the present invention are all lower than that of 2-tert-butyl-4-methoxyphenol-oxyl (BHA), indicating better safty.
Table 3.Experimental results of acute toxicity in mice of some compounds compound LD 50 BHA 1100 XH2006 >1200 XH2010 >1200 XH2011 >1300 XH2044-2 >1300 Industrial application The advantages of the present invention lie in: 1) the compound provided by the present invention can slowly release 2-tert-butyl-4-methoxyphenol in vivo, overcoming the disadvantage that the half-life of 2-tert-butyl-4-methoxyphenol directly adminisitered in the body is short (T/2=0.5~1h), and maintains stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T1/2=1224h). 2) The equivalent dose of the compound provided by the present invention is lower, and for achieveing the same plasma concentration and the curve of similar drugs (AUC), the administrating dose of the compound of the present invention is merely 1/100-1/5000 of the directly adminisitered dose of 2-tert-butyl-4-methoxyphenol, avoiding the toxic effect resulted from 2-tert-butyl-4-methoxyphenol with high dose.
3) the cytotoxicity of the compound provided by the present invention is lower when compared with that of 2-tert-butyl-4-methoxyphenol, and the acute toxicity of part of the compounds in mice (LD5o>1200mg/kg) is lower than that of 2-tert-butyl-4 methoxyphenol (LD 5 o=1100mg/kg). 4)the compound provided by the present invention protects the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoids the oxidation in the environment and increases the enviromental stability of the drugs. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (1)

  1. The claims defining the invention are as follows:
    1. A compound of formula I, or a pharmaceutically acceptable salt, hydrate or
    solvate thereof,
    formula I wherein: when X is C=O and Y is NH, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having 1-40 carbon atom(s), a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, benzene rings, pyridine, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; when X is C=O and Y is absent, R is selected from any one of the following groups: 1) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 2) a unsubstituted alkyl group having 7-40 carbon atoms; 3) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 4) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 5) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan or pyrrole ; 6) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; 7) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or 8) a substituted aryl group or heteroaryl group containing at least four carbon atoms;the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide.
    2. The compound of formula I, or pharmaceutically acceptable salt, hydrate or solvate thereof, according to claim 1, selected from from the group consisting of: 2) (2-tert-butyl-4-methoxyphenol) (N-n-butyl)carbamate, 3) (2-tert-butyl-4-methoxyphenol) (N-isopropyl)carbamate, 4) (2-tert-butyl-4-methoxyphenol) (N-cyclohexyl)carbamate, 9) 2-tert-butyl-4-methoxyphenol nicotinate, 10) 2-tert-butyl-4-methoxyphenol isonicotinate, 11) 2-tert-butyl-4-methoxyphenol cyclohexenecarboxylate, 13) 2-tert-butyl-4-methoxyphenol acrylate, 14) (2-tert-butyl-4-methoxyphenol) 3,4-dimethoxyphenylacetate, 15) 2-tert-butyl-4-methoxyphenol butynoate, 16) bis(2-tert-butyl-4-methoxyphenol) 2,2'-biphenyldicarboxylate, 19) (2-tert-butyl-4-methoxyphenol) (1H-indole-3-yl)acetate, 21) (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonylpiperidine-3-formate, 22) di(2-tert-butyl-4-methoxyphenol) terephthalate, 24) (2-tert-butyl-4-methoxyphenol) 4-phenylbenzoate, 27) 2-tert-butyl-4-methoxyphenol hexadecylate, 28) N-tert-butoxycarbonylglycine(2-tert-butyl-4-methoxyphenol)ester, 32) (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonylalaninate, 33) (2-tert-butyl-4-methoxyphenol) 2-naphthoate, 34) di(2-tert-butyl-4-methoxyphenol) malonate, 35) (2-tert-butyl-4-methoxyphenol) 3,6-dichloropyridazine-4-formate, 36) (2-tert-butyl-4-methoxyphenol) 1-methylcyclopropyl formate, 37) (2-tert-butyl-4-methoxyphenol) 2-indoleformate, 38) (2-tert-butyl-4-methoxyphenol) 2-chloro-3-picolinate, 39) (2-tert-butyl-4-methoxyphenol) 2-thiopheneacetate,
    40) (2-tert-butyl-4-methoxyphenol) 3-(4-methylphenyl)-propionate, 41) (2-tert-butyl-4-methoxyphenol) propiolate, 43) (2-tert-butyl-4-methoxyphenol) 2-fluoropropionate, 45) (2-tert-butyl-4-methoxyphenol) cyclopentanecarboxylate, 46) (2-tert-butyl-4-methoxyphenol) adamantaneacetate, 48) (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonylpiperidine-4-formate, 49) (2-tert-butyl-4-methoxyphenol) octanoate, 50) (2-tert-butyl-4-methoxyphenol) 7-oxooctanoate, 51) (2-tert-butyl-4-methoxyphenol) cyclohexene-2-carboxylate, 54) (2-tert-butyl-4-methoxyphenol) 2-fluoro-4-nitryl benzoate, 55) (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonylpiperidine-3-formate, 56) di(2-tert-butyl-4-methoxyphenol) p-phenylenediacetate, 57) (2-tert-butyl-4-methoxyphenol) 4-benzoyl butyrate, 58) (2-tert-butyl-4-methoxyphenol) 3,5-dimethoxy phenylpropenoate, 59) (2-tert-butyl-4-methoxyphenol) 4-chloropyridine-2-formate, 60) (2-tert-butyl-4-methoxyphenol) N-methylpiperidine-3-formate, 61) (2-tert-butyl-4-methoxyphenol) N-tert-butoxycarbonyl-5-amino pentanoate,62) (2-tert-butyl-4-methoxyphenol) 3,3,3-trifluoropropionate, 63) (2-tert-butyl-4-methoxyphenol) morpholin-4-yl acetate, 65) di(2-tert-butyl-4-methoxyphenol) adipate.
    3. A compound selected from the group consisting of 1) (2-tert-butyl-4-methoxyphenol) (N-benzyl)carbamate,
    5) (2-tert-butyl-4-methoxyphenol) (N-phenethyl)carbamate,
    12) 2-tert-butyl-4-methoxyphenol propionate, 18) (2-tert-butyl-4-methoxyphenol) 3-fluorophenylacetate,
    20) (2-tert-butyl-4-methoxyphenol) 3-(4-fluorophenyl)-propionate,
    23) (2-tert-butyl-4-methoxyphenol) 3-(3-nitrophenyl)propionate, 25) (2-tert-butyl-4-methoxyphenol) 4-methylpyridine-3-formate,
    26) (2-tert-butyl-4-methoxyphenol) 4-methoxypyridine-3-formate,
    31) (2-tert-butyl-4-methoxyphenol) 3-cyanobenzoate, 42) (2-tert-butyl-4-methoxyphenol) 2-phenyl propionate,
    44) (2-tert-butyl-4-methoxyphenol) cyclohexyl acetate,
    47) (2-tert-butyl-4-methoxyphenol) cyclopropylacetate,
    52) (2-tert-butyl-4-methoxyphenol) 2,4,5-trifluorophenylacetate, 64) (2-tert-butyl-4-methoxyphenol) 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)
    propionate,
    or a pharmaceutically acceptable salt, hydrate or solvate thereof.
    4. A method of preparing the compound of formula I, or pharmaceutically acceptable salt, hydrateor solvatethereof, according to claim 1 or 2, comprising the following steps (1), (2), (3) or (4): (1) when X is C=O and Y is NH, the method comprises: reacting RNH2 with triphosgene to obtain R-N=C=O; obtaining the compound of formula I via a condensation reaction of R-N=C=O with 2-tert-butyl-4-methoxyphenol;
    O -Ys R
    formula I wherein, in formula I, in RNH2 and R-N=C=0, R is selected from any one of the following groups: a substituted or unsubstituted alkyl group having 1-40 carbon atom(s), a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms, and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, benzene rings, pyridine, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethyleneglycol, polyglutamic acid or polysaccharide; and wherein in formula I, X is C=O and Y is NH; (2) when X is C=O and Y is absent, that is a compound of formula II, the method comprises the following step 1) or 2): 1) obtaining a compound as shown by formula II via condensation of 2-tert butyl-4-methoxyphenol sodium with acyl chloride as shown by formula 2;
    O R 0
    0 O CI R formula II formula 2 wherein in formula II and formula 2, R is selected from any one of the following groups: a) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; b) a unsubstituted alkyl group having 7-40 carbon atoms; c) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; d) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; e) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan, or pyrrole; f) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are selected from halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; g) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or h) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; and wherein in formula II, X is C=O; or 2) obtaining the compound of formula II via condensation of 2-tert-butyl-4 methoxyphenol sodium with carboxylic acid as shown by formula 3;
    O1 X R O
    S"HO R formula II formula 3 wherein in formula II and formula 3, R is selected from any one of the following groups: a) a substituted alkyl group having 2-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; b) a unsubstituted alkyl group having 7-40 carbon atoms; c) a substituted or unsubstituted cycloalkyl group having 3-40 carbon atoms; the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; d) a substituted or unsubstituted alkenyl group or alkynyl group having 2-40 carbon atoms; the substituent groups in R are nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; e) an unsubstituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, pyridine, purine, pyrimidine, imidazole, furan, or pyrrole; f) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is naphthalene rings, indole, purine, pyrimidine, imidazole, furan, pyrrole or benzoheterocycle; wherein the substituent groups in R are halogen, nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; g) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is pyridine; wherein the substituent groups in R are selected from nitro group, natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; or h) a substituted aryl group or heteroaryl group containing at least four carbon atoms; the aryl group or heteroaryl group is benzene rings; wherein the substituent groups in R are selected from natural flavone, polyethylene glycol, polyglutamic acid or polysaccharide; and wherein in formula II, X is C=O.
    5. A pharmaceutical composition comprising a compound of formula I according to claim 1 or 2, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a compound of according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable carrier.
    6. Use of a compound of formula I according to claim 1 or 2, or a pharmaceutically acceptable salt, hydrate or solvate thereof, a compound of according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 5, in the manufacture of a medicament for the treatment of a tumor or a disease/disorder associated with modulation of macrophages.
    7. The use according to claim 6, wherein the medicament releases 2-tert-butyl 4-methoxyphenol when administered to a subject.
    8. A method of treating a tumor or a disease/disorder associated with modulation of macrophages comprising administering a therapeutically effective amount of a compound of formula I according to claim 1 or 2, or a pharmaceutically acceptable salt, hydrate or solvate thereof, a compound of according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 5, to a subject in need thereof.
    9. The method according to claim 8, wherein the medicament releases 2-tert butyl-4-methoxyphenol when administered to a subject.
    10. Use of a compound of formula I according to claim 1 or 2, or a pharmaceutically acceptable salt, hydrate or solvate thereof, a compound of according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 5, as a prodrug for releasing 2-tert-butyl-4-methoxyphenol.
    BHA - BHA treated group Control group Figure 1 BHA plasma concentration (ng/ml)
    Drug Concentration-Time profiles for female mice
    Time (min) BHA plasma concentration (ng/ml)
    Drug Concentration-Time profiles for male mice
    Time (min)
    Figure 2
    1/19
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    /19 Incubating time (h) Incubating time (h)
    Incubating time (h) 10000 Peak area XH2025 10000 Peak area XH2024 10000 Peak area XH2023
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    /19 Incubating time (h) Incubating time (h)
    Incubating time (h) 10000 XH2038-5 Peak area 10000 XH2038-4 Peak area 10000 XH2038-3 Peak area
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    11/19 Incubating time (h) Incubating time (h)
    Incubating time (h) 10000 XH2039-3 Peak area 10000 XH2039-2 Peak area 10000 XH2039-1 Peak area
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    12/19 Incubating time (h)
    Incubating time (h) Incubating time (h)
    10000 XH2039-6 Peak area 10000 XH2039-5 Peak area 10000 XH2039-4 Peak area
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    14/19 Incubating time (h) Incubating time (h)
    Incubating time (h) 10000 XH2041-2 Peak area 10000 XH2041-3 Peak area 10000 XH2040-5 Peak area
    BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml) BHA plasma concentration (ng/ml)
    16/19 Incubating time (h) Incubating time (h) Incubating time (h)
    10000 XH2043-2 Peak area 10000 1000 XH2043-1 Peak area 10000 XH2043-3 Peak area
    BHA plasma concentration (ng/ml)
    Time (h)
    19/19 Figure 4
AU2017209362A 2016-01-20 2017-02-22 Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation Active AU2017209362B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610037849.5A CN106986789B (en) 2016-01-20 2016-01-20 Hydroquinone compound and preparation method thereof and the application in antitumor or immunological regulation
CN201610037849.5 2016-01-20
PCT/CN2017/074386 WO2017125093A1 (en) 2016-01-20 2017-02-22 Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation

Publications (2)

Publication Number Publication Date
AU2017209362A1 AU2017209362A1 (en) 2018-02-22
AU2017209362B2 true AU2017209362B2 (en) 2021-01-28

Family

ID=59361391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017209362A Active AU2017209362B2 (en) 2016-01-20 2017-02-22 Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation

Country Status (7)

Country Link
US (2) US10786481B2 (en)
EP (1) EP3398934A4 (en)
JP (1) JP6659828B2 (en)
CN (1) CN106986789B (en)
AU (1) AU2017209362B2 (en)
RU (1) RU2708464C2 (en)
WO (1) WO2017125093A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108929202B (en) * 2017-05-24 2021-02-19 中国人民解放军军事医学科学院生物医学分析中心 Novel preparation method and novel crystal form of 2-tert-butyl-4-methoxyphenol

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1282658A (en) * 1969-07-23 1972-07-19 Merck Patent Gmbh Stabilisation of organic products with phenol ethers and phenol esters
JPS5584934A (en) * 1978-12-20 1980-06-26 Fuji Photo Film Co Ltd Color photographic material
EP0045990A1 (en) * 1980-08-07 1982-02-17 Farmatis S.r.l. Novel antibacterial and antiprotozoal derivatives, a process for the preparation thereof, and related pharmaceutical compositions
US4649219A (en) * 1984-03-13 1987-03-10 Mitsui Toatsu Chemicals, Incorporated Unsaturated cyclic amido-substituted ether compounds and preparation process thereof
US5362615A (en) * 1992-09-01 1994-11-08 Agfa Ag Photographic recording material containing a hydroquinone diether compound
EP1308311A2 (en) * 2001-10-31 2003-05-07 Eastman Kodak Company Ink jet recording element and printing method
JP2009256142A (en) * 2008-04-17 2009-11-05 Kyushu Institute Of Technology p-TYPE SINGLE CRYSTAL ZnO
WO2014035149A1 (en) * 2012-08-30 2014-03-06 Chong Kun Dang Pharmaceutical Corp. N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
WO2014048865A1 (en) * 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag New bicyclic derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1308311A (en) * 1919-07-01 Eaves-tbotjekh pbotectob
US1937384A (en) * 1929-08-19 1933-11-28 Hess Jacob Just Combined coin purse and bill fold
JPS54147038A (en) * 1978-05-10 1979-11-16 Fuji Photo Film Co Ltd Silver halide color emulsion
FR2653119B1 (en) * 1989-10-18 1994-08-05 Lipha NOVEL ARYLOXY ALCOYL BENZENES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
CH690163A5 (en) 1995-07-28 2000-05-31 Symphar Sa Derivatives substituted gem-diphosphonates useful as anti-cancer.
JPH09278741A (en) * 1996-04-10 1997-10-28 Tanabe Seiyaku Co Ltd Phenol derivative
JPH1135568A (en) * 1997-05-23 1999-02-09 Chugai Pharmaceut Co Ltd 2,3-dihydrobenzofuran derivative
TW472051B (en) * 1997-05-23 2002-01-11 Chugai Pharmaceutical Co Ltd 2,3-dihydrobenzofuran derivatives
JP5651291B2 (en) * 2008-04-11 2015-01-07 株式会社センカファーマシー Polyethylene glycol derivative and process for producing the intermediate
KR101376260B1 (en) * 2008-04-14 2014-03-20 삼성전자 주식회사 Semiconductor device and method for fabricating the same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1282658A (en) * 1969-07-23 1972-07-19 Merck Patent Gmbh Stabilisation of organic products with phenol ethers and phenol esters
JPS5584934A (en) * 1978-12-20 1980-06-26 Fuji Photo Film Co Ltd Color photographic material
EP0045990A1 (en) * 1980-08-07 1982-02-17 Farmatis S.r.l. Novel antibacterial and antiprotozoal derivatives, a process for the preparation thereof, and related pharmaceutical compositions
US4649219A (en) * 1984-03-13 1987-03-10 Mitsui Toatsu Chemicals, Incorporated Unsaturated cyclic amido-substituted ether compounds and preparation process thereof
US5362615A (en) * 1992-09-01 1994-11-08 Agfa Ag Photographic recording material containing a hydroquinone diether compound
EP1308311A2 (en) * 2001-10-31 2003-05-07 Eastman Kodak Company Ink jet recording element and printing method
JP2009256142A (en) * 2008-04-17 2009-11-05 Kyushu Institute Of Technology p-TYPE SINGLE CRYSTAL ZnO
WO2014035149A1 (en) * 2012-08-30 2014-03-06 Chong Kun Dang Pharmaceutical Corp. N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
WO2014048865A1 (en) * 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag New bicyclic derivatives

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number: 748010-49-3; STN Entry Date: 19 Sep 2004; Chemical Name: 2-Benzofurancarboxylic acid, 2-(1,1-dimethylethyl)-4-methoxyphenyl ester *
CAS Registry number: 926426-70-2; STN Entry Date: 14 Mar 2007; Chemical Name: 2-Pyridinecarboxylic acid, 3,4,5-trichloro-, 2-(1,1-dimethylethyl)-4-methoxyphenyl ester *
CAS Registry number: 926868-22-6; STN Entry Date: 18 Mar 2007; Chemical Name: 1,2,4]Triazolo[1,5-a]pyrimidine-6-propanoic acid, 5,7-dimethyl-2-(methylthio)-, 2-(1,1-dimethylethyl)-4-methoxyphenyl ester *
MOSNACEK J ET AL, "New combined phenol/hindered amine photo- and thermal-stabilizers based on toluene-2,4-diisocyanate", POLYMER DEGRADATION AND STABILITY, 2002, vol. 80, no. 1, pages 113 - 126 *
NASSER IRANPOOR ET AL, "Easily Prepared Azopyridines As Potent and Recyclable Reagents for Facile Esterification Reactions. An Efficient Modified Mitsunobu Reaction", JOC, (2008), vol. 73, no. 13, pages 4882 - 4887 *
SHEALY, Y.F. et al., "Inhibition of Papilloma Formation by Analogues of 7, 8-Dihydroretinoic Acid", JOURNAL OF MEDICINAL CHEMISTRY, (2003-05-08), vol. 46, no. 10, pages 1931 - 1939 *
SHINDO RYODAI ET AL, "Critical contribution of oxidative stress to TNF[alpha]-induced necroptosis downstream of RIPK1 activa", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2013), vol. 436, no. 2, pages 212 - 216 *

Also Published As

Publication number Publication date
EP3398934A4 (en) 2019-11-27
EP3398934A1 (en) 2018-11-07
RU2018111766A3 (en) 2019-10-02
WO2017125093A1 (en) 2017-07-27
US20190022049A1 (en) 2019-01-24
JP2018526350A (en) 2018-09-13
RU2708464C2 (en) 2019-12-09
CN106986789B (en) 2019-07-16
US10786481B2 (en) 2020-09-29
CN106986789A (en) 2017-07-28
US11738000B2 (en) 2023-08-29
US20210008022A1 (en) 2021-01-14
JP6659828B2 (en) 2020-03-04
AU2017209362A1 (en) 2018-02-22
RU2018111766A (en) 2019-10-02

Similar Documents

Publication Publication Date Title
JP5795630B2 (en) Cyclopropyldicarboxamide and analogs exhibiting anticancer and antiproliferative activity
CA2726588C (en) Compounds and methods for treating inflammatory and fibrotic disorders
CA2774133C (en) Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
JP6207393B2 (en) Novel immunomodulators and anti-inflammatory compounds
JP6362610B2 (en) Therapeutic compounds and compositions and their use as PKM2 modulators
US20100130737A1 (en) Regulating Agent of GPR34 Receptor Function
JP2016028037A (en) Pyrazole derivative modulator of calcium release-activated calcium channel and method for treatment of non-small cell lung cancer
KR102232744B1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
JPH11302173A (en) Histone deacetylase inhibitor
KR20130121818A (en) Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins
JPH11263789A (en) Purine derivative and adenosine a2 receptor antagonist as agent for preventing and treating diabetes
JPH11269140A (en) Differentiation-inducing agent
JP6953538B2 (en) Biaryl compound, its production method and application
AU2017209362B2 (en) Hydroquinone compound, preparation method therefor, and application in tumour resistance or immunomodulation
WO2015021894A1 (en) Novel hydroximic acid derivative and medical application thereof
ES2527137T3 (en) Phenanthrenone compounds, compositions and procedures
JP2015533778A (en) Novel phenyl-pyridine / pyrazine amide for the treatment of cancer
KR101879992B1 (en) Compounds inhibiting formation of c-Myc/Max/DNA complex
CN115427407B (en) Novel N-heterocyclic BET bromodomain inhibitor, preparation method and medical application thereof
CN116903581A (en) SHP2/HDAC double-target inhibitor and preparation method and application thereof
CN103933032B (en) The application method and purposes of pyrazole derivatives as anticancer drug

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)